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Unsafe abortions pose serious threats to women’s health. Medical abortion provides safer 
abortion access to many. The lengthy interval between misoprostol and mifepristone 
creates multiple barriers for women and providers.   A paucity of research exists about 
medical abortion protocols that allow single day procedures. The efficacy and the safety 
of 3 medical abortion protocols of varying lengths were explored in this study.   A 
secondary data set of over 55,000 patients from the United Kingdom was retrospectively 
analyzed using binomial logistic regression. Efficacy results showed no significant 
difference between the conventional and the simultaneous protocols; when compared to 
those, the 6- to 8- hour protocol showed a 79% higher risk (OR = 0.210, 95% CI = 0.178 
- 0.246) of failure. Safety of the simultaneous protocol was 48% lesser (OR = 0.524, 95% 
CI = 0.447 - 0.613) and the safety of the 6- to 8- hour protocol 61% lesser (OR = 0.386, 
95% CI = 0.304- 0.489) compared to the conventional protocol. The absolute risk of 
complications or severe adverse events of all protocols (0.98%, 1.97%, and 2.67%) was 
very low. The results suggest the simultaneous protocol is a viable alternative to the 
conventional protocol up to 10 weeks’ gestation. The results could promote the adoption 
of the simultaneous protocol by health systems, give millions more women access to safe 
and effective single day medical abortions, reduce the need for skilled clinicians, and 
reduce cost burdens for both women and for healthcare systems overall. Implementation 
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Chapter 1: Introduction to the Study 
Introduction 
According to Devereux (1954, p. 98), “Abortion is an absolutely universal 
phenomenon, and it is impossible to construct an imaginary social system in which no 
woman would ever feel at least compelled to abort”. The world saw an estimated 200–
220 million pregnancies in the years after 2010 (Vrachnis et al., 2016). Approximately 
40% (i.e., 85 million) of these pregnancies were unintended, and over half of the 
unintended pregnancies (i.e., approximately 40 million pregnancies) were aborted 
(Sedgh, Singh, & Hussain, 2014). Over half of those 40 million abortions were carried 
out in an unsafe manner (Sedgh et al., 2014; Vrachnis et al., 2016). In 2015, there were 
303,000 maternal deaths globally (Filippi et al., 2016). The World Health Organization 
(WHO; 1992) defined a maternal death as “the death of a woman whilst pregnant or 
within 42 days of delivery or termination of pregnancy, from any cause related to, or 
aggravated by pregnancy or its management, but excluding deaths from incidental or 
accidental causes” (p. 2). Unsafe abortion has been estimated to cause 4.7% to 15% of the 
maternal deaths in 2015 (Filippi et al., 2016). 
Surgical and medical methods are used for inducing abortion. With 
prostaglandins, such as misoprostol (MISO), becoming available in the early 1970s and 
antiprogestins, such as mifepristone (MIFE), in the 1980s, medical abortion (MA), the 
induction of abortion using medication alone (Gopal et al., 2017) became an alternative 
to surgical methods (Kulier et al., 2004). MA is safer, cheaper, and less medicalized 
compared to surgical methods (Simmonds, Beal, & Eagen‐Torkko, 2017; Zane, et al., 
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2015). Protocols of MIFE and MISO, separated by a dosing interval is the norm for MA 
(Gatter et al., 2015; Raymond et al., 2013). This interval has remained at 24-to 48-hours 
over the last 2 decades (Creinin et al., 2004; WHO, 2015), making MA longer than 
surgical abortion. 
In this study, I compared the efficacy and the safety of three MA protocols. The 
protocols differed based on their dosing intervals between MIFE and MISO while having 
the same dosages of the two drugs and the same route for administering MISO. The first 
uses a 24- to 36-hour dosing interval, the second a 6-hour dosing interval, and the third 
eliminates the interval, with the two drugs being administered simultaneously. The latter 
two shorter protocols, if found to have acceptable levels of safety and efficacy, could 
eventually replace the current MA protocol. This could pave the way for MA to become a 
shorter, simpler procedure and increase access for many more women. If the efficacy and 
the safety of either of the latter protocols is found to be acceptable, it could replace the 
conventional protocol and potentially turn MA in to a single day process. That could 
make MA both more enticing and accessible to millions of women worldwide. Even if 
the safety and efficacy of the shorter protocols are inferior in comparison, knowing the 
exact safety and efficacy of those protocols could still allow one or both to be offered as 
an alternative option to women who seek a safe and convenient MA, following robust 
counselling on the protocol choices. That too, could make MA more appealing and 
accessible to millions of women. 
I will use this chapter to introduce the study. I will provide a brief overview of the 
study by explaining the background of the study, the problem statement focused on the 
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gap that I intended to fill with this study, and the purpose of the study. I will also present 
the research questions and the hypotheses along with the variables of the study. The 
theories that were used to guide this study and form its theoretical foundation will then be 
outlined. Definitions of the different terms related to the field of MA that were used in 
the study will be included in this chapter. I will also explain the nature of the study and 
examine its limitations. Finally, I will outline the significance of the study from the 
perspectives of public health and social change. 
Background of the Study 
Since MIFE was introduced in France and China more than 2 decades ago, MA 
with this antiprogestin has expanded rapidly throughout the world. MIFE is now 
registered in 57 countries (Dunn & Cook, 2014). In the United States, about one fifth of 
all outpatient abortions are performed medically (Jones & Kooistra, 2011), and in several 
countries in Europe, the proportion exceeds 60% (Jones & Henshaw, 2002). Many 
aspects of different MA protocols have been studied at various gestational ages. The next 
frontier in MA research appears to be the shortening of the process by shortening the 
dosing interval; however, only 13 studies have explored MA protocols with dosing 
intervals below 12 hours. Pymar, Creinin, and Schwartz (2001) and Creinin et al. (2004) 
showed MIFE 200 mg and vaginal MISO 800 μg with a 6- to 8-hour dosing interval has 
comparable efficacy to the conventional protocol (i.e., 24- to 36-hour dosing interval) at 
gestational ages below 49 days. 
Fox, Creinin, and Harwood (2002) and Guest et al. (2007) showed that 
comparative efficacy extends up to 63 days of gestation. Creinin et al. (2004), authors of 
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the first randomized trial, also showed comparable efficacy between the 6-to 8-hour 
dosing interval and the conventional protocol. Protocols with simultaneous dosing at 
gestational ages up to 49 days (Li et al., 2006; Li et al., 2011; Murthy, Creinin, Harwood, 
& Schreiber, 2005), 56 days (Kapp, Borgatta, Ellis, & Stubblefield, 2006), and 63 days 
(Creinin et al., 2007; Schreiber, Creinin, Harwood, & Murthy, 2005) have been shown to 
have expulsion rates of approximately 90%. Only Lohr et al. (2007) showed simultaneous 
dosing to have expulsion rates below 80% at gestational ages up to 63 days. During my 
exhaustive literature review, I found neither studies that compared more than two 
protocols nor studies that included more than one short MA protocol. Furthermore, I 
found no author that had conducted a retrospective analysis of a large data set of MA 
clients who had the procedure in a non-research setting. 
The aforementioned gaps in the literature helped highlight the need for my study. 
Women, especially in resource-poor countries, need access to the shortest and simplest 
possible methods available to terminate a pregnancy when they choose to do so. Clinical 
providers need to offer the simplest and shortest MA options. Their ability to offer a 
choice in MA protocols to women could increase the percentage of safe abortions done 
using medical options. Finally, providers need to be able to accurately counsel women on 
the efficacy and the safety of the MA protocols that they offer. The results of this study 
could help determine which method is the best for them. 
Problem Statement 
Unsafe abortion accounts for between 7% and 15% of global maternal deaths 
(Kassebaum et al., 2014). Of the 213 million pregnancies in world in 2012, 40% were 
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unintended and over 20% were aborted. More than half of all abortions in the world were 
unsafe (Sedgh et al., 2014, Vrachnis et al., 2016).  MA is the induction of abortion using 
abortifacient medication alone (Gopal et al., 2017). It is a viable alternative to surgical 
options that is growing in popularity (Gatter, Cleland, & Nucatola, 2015; Ngo, Park, 
Shakur, & Free, 2011). MA allows safe, cheaper abortion services in demedicalized 
settings (Raymond, Shannon, Weaver, & Winikoff, 2013). Regimens of MIFE followed 
by MISO after a time gap is the norm for MA (Gatter et al., 2015; Raymond et al., 2013). 
This time gap has remained at 24 hours or more over the last 2 decades (Creinin et al., 
2004; WHO, 2015) and makes MA a much longer process than surgical abortion. 
Furthermore, many countries do not allow the self-use of either drug (Gatter et al., 2015). 
Due to these reasons, women who want to have a MA are forced to stay in a health 
facility for over a day, make two or more visits, or take one or both drugs and complete 
the expulsion with no clinical supervision (Aiken et al., 2017).  A shorter time protocol 
that is just as effective and safe could relieve these burdens. 
Despite the future of MA research seeming to lay in finding ways to make MA 
shorter and simpler, little research has been conducted in this field. I could find only 13 
studies that studied MA protocols with dosing intervals of less than 12 hours have been 
published over the last 15 years. These started with Pymar et al. (2001) studying a 6- to 
8-hour dosing interval and ended with Verma et al. (2017) who studied a simultaneous 
dosing protocol. There are multiple gaps in this body of literature on shorter MA 
protocols. I could not discover any study that simultaneously compared more than two 
protocols. I also failed to discover any study that compared the 6-to 8-hour dosing 
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interval with simultaneous dosing. None of the authors in the 13 short-protocol studies 
pointed out these areas as requiring further research. The other significant gap was in 
secondary analyses of real MA patient data of any short MA protocol in any setting. All 
13 published studies on short MA protocols were prospective studies, where the authors 
started gathering data knowing that the clients’ outcomes would be analyzed for 
publication. 
In this study, I will present efficacy and safety analyses based, for the first time, 
on a large, retrospective data set where the women underwent MA without a research 
setting. Such analyses of large patient data sets could uncover efficacy differences 
between these protocols administered in a research setting versus in day-to-day clinical 
practice. Another relevant gap in the literature exists around studies of 6- to 8-hour 
dosing intervals and simultaneous dosing in the United Kingdom. Guest et al.’s (2007) 
research represents the only published study that explored the protocol using the 6- to 8-
hour dosing interval in the United Kingdom, while Lohr et al. (2007) is the only 
published UK-based study that explored the simultaneous dosing protocol. Both these 
studies have relatively small sample sizes, with Guest et al. having 215 women on the 6- 
to 8-hour dosing interval and Lohr et al. having 120 women in total. The United 
Kingdom differs from many countries with liberal abortion legislature in that home 
administration of any abortifacient is not allowed under criminal law (Francome, 2017). 
Analyzing the safety of the efficacy of both the 6- to 8-hour dosing interval and 
simultaneous dosing, my study findings could offer information that is of great value to 
women and healthcare providers in the United Kingdom and should be studied further. 
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Purpose of the Study 
In this study, I employed a quantitative design and used regression analyses to 
explore the relationships of different MA protocols with different dosing intervals to the 
efficacy and safety of the procedures resulting from those protocols. In exploring the 
relationship between a MA protocol and the resulting safety of the procedure, I controlled 
for factors that have been shown to impact the safety of MAs conducted using MIFE and 
MISO (i.e., gestational age and the age of the pregnant woman). In exploring the 
relationship between the MA protocol and the efficacy of the procedure, I controlled for 
factors that have been shown to impact the efficacy of MAs conducted using MIFE and 
MISO (i.e., gestational age, maternal age, and the number of past deliveries). Hence, I 
had one independent variable (i.e., MA protocol, decided by the dosing interval). This 
variable had three levels (i.e., dosing interval of 24- to 36-hours, dosing interval of 6-to 
8-hours, and simultaneous dosing). There were two dependent variables: safety (decided 
based on whether a given client faced a complication that required healthcare or not) and 
efficacy (decided based on whether a given client required an intervention to complete 
evacuation due to MA failure). Each of these variables had two levels (i.e., efficacious or 
not, and safe or unsafe). There were three control variables. Gestational age and the 
maternal age at the procedure were controlled for when exploring the relationship 
between the MA protocol and the safety of the procedure. I controlled for all three (i.e., 
gestational age, maternal age, and the number of past pregnancies) when exploring the 
relationship between the MA protocol and the efficacy of the procedure. 
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Research Questions and Hypotheses 
Research Question 1: What is the relationship between the MA protocol time gap 
(i.e., 6 hours vs. 24 to 36 hours vs. simultaneous) and the safety of the procedure 
as measured by the percentage of women who experienced a complication that 
required medical care after controlling for factors that impact the safety of MAs 
conducted using MIFE and MISO (i.e., gestational age and maternal age)? 
H01: There is no statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24 to 36 hours vs. simultaneous) and 
the safety of the procedure as measured by the percentage of women who 
experienced a complication that required medical care after controlling for 
factors that impact the safety of MAs conducted using MIFE and MISO 
(i.e., gestational age and maternal age). 
HA1: There is a statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24 to 36 hours vs. simultaneous) and 
the safety of the procedure as measured by the percentage of women who 
experienced a complication that required medical care after controlling for 
factors that impact the safety of MAs conducted using MIFE and MISO 
(i.e., gestational age and maternal age). 
Research Question 2: What is the relationship between the MA protocol time gap 
(i.e., 6 hours vs. 24 to 36 hours vs. simultaneous) and the efficacy of the 
procedure as measured by the percentage of women who required a second 
intervention to complete the expulsion after controlling for factors that impact the 
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effectiveness of MIFE and MISO (i.e., gestational age, maternal age, and the 
number of past deliveries)? 
H02: There is no statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24to 36 hours vs. simultaneous) and the 
efficacy of the procedure as measured by the percentage of women who 
required a second intervention to complete the expulsion after controlling 
for factors that impact the effectiveness of MIFE and MISO (i.e., 
gestational age, maternal age, and the number of past deliveries). 
HA2: There is a statistically significant difference between the MA 
protocol time gap (6 hour vs. 24 to 36 hours vs. simultaneous) and the 
efficacy of the procedure as measured by the percentage of women who 
required a second intervention to complete the expulsion after controlling 
for factors that impact the effectiveness of MIFE and MISO (i.e., 
gestational age, maternal age, and the number of past deliveries). 
Theoretical Foundation 
The framework of this quantitative study was formed by postpositivism and 
empiricism (Theory of Knowledge, 2015). The linear, uni-directional nature of my study 
design aligns with positivism; however, the relative complexity of postpositivism when 
compared to positivism (see Tashakkori & Teddlie, 1998) was a better fit, especially 
when interpreting and generalizing the findings. Postpositivism is not limited to the 
observable (Clark, 1998) and holds that objectivity is an ideal but requires critical 
interpreters (Fischer, 1998). Postpositivism takes a realist perspective of science and 
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demands that science requires precision, logical reasoning, and attention to evidence 
(Theory of Knowledge, 2015). If, at the end of my study, I found that the two shorter 
protocols (or one of them) had efficacy and safety values that were acceptable (albeit 
lower in comparison to the conventional protocol), the postpositivist approach would 
allow me to recommend such a protocol for wide use given the benefits (both subjective 
and objective) that it would bring to women across nations. Tashakkori and Teddlie 
(1998) showed that studies grounded in a postpositivist framework allow subjectivity as 
well as allow researchers to take the realities of life at the point in time into account while 
interpreting their results. Postpositivism is well aligned with the ability of a simpler MA 
protocol to possibly improve women’s subjective MA experience by shortening the time 
needed and removing the need for an overnight experience.  Grounding my study in a 
postpositivist theoretical framework allowed me to follow an objective path and set aside 
my views of abortion and my opinion of MA. The postpositivist approach allowed me to 
remain objective, for observers with varying stances on abortion can set them aside and 
focus on the tangible, quantitative, observation-based findings.  
Empiricism stresses that observation and measurement form the core of scientific 
study (Trochim, 2006). Baird and Kaufmann (2008) showed how researchers who design 
studies grounded through empiricism recognize empirical evidence and the knowledge 
received through observation and experimentation in the formation of ideas. In my study, 
I derived results and conclusions using a quantitative, scientific approach and measured 
the efficacy and the safety of the MA protocols by scientific analysis of observed, 
retrospective, patient data. The empirical approach I used in this study was reductionist, 
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reducing research ideas into a small, discrete set of variables that comprise hypotheses 
and research questions (see Creswell, 2013). Empiricism was aligned with this study by 
assessing the effectiveness of the outcomes of those receiving a new intervention 
compared with outcomes of the group who received the conventional regimen (see 
Davies & Nutley, 1999).  
Olsen (2004) claimed empiricism is behind a mathematics-fetishism that 
promotes quantitative study and puts off qualitative research. While meant as a criticism, 
the claim showed that empiricism was a good fit for this study where objective, 
quantitative analyses of independent, dependent, and control variables were conducted 
with the aim of quantifying the efficacy and safety of different MA protocols. I 
developed the hypotheses of this study to focus on objective efficacy and safety outcomes 
of three MA protocols. A postpositivist and empiricist approach supported measuring the 
efficacy and the safety of MA protocols using objective, measurable, independent, 
dependent, and control variables as well as the interpretation of the findings without 
discarding subjective benefits for women. 
Nature of the Study 
In this study, I conducted a retrospective analysis of a large secondary data set 
from one of the largest abortion care providers in the United Kingdom. Authors who 
discussed research study designs (i.e., Creswell, 2013; Frankfort-Nachmias & Nachmias, 
2008) as well as authors of past quantitative studies that explored abortion outcomes and 
abortion safety (Li et al. 2011; Tendler et al., 2015; Verma et al., 2017) provided 
rationale for my study design choice. Secondary data use and retrospective designs allow 
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large sample sizes to be studied with much lower burdens in terms of resources, logistics, 
and time (Creswell, 2013; Frankfort-Nachmias & Nachmias, 2008). A retrospective 
cohort analysis of a large secondary data set allowed me to include large sample sizes 
under each of the three protocols without infringing on women seeking a MA being able 
to choose their preferred protocol. The data set includes the medical records of over 
25,000 women who underwent MA services within 1 calendar year from the abortion 
provider. I was able to find adequate sample sizes for each of the three MA protocols 
from within this large data set, allowing me to conduct this study with good power and 
confidence intervals. 
Past authors of quantitative studies who compared or measured the efficacy and 
the safety of various MA protocols have commonly used quantitative designs. In their 
systematic review on the effectiveness, safety, and acceptability of MA protocols, 
Sjöström et al. (2017) focused on six studies that assessed these parameters; all six had 
quantitative, cohort analysis designs. In their systematic review of the clinical outcomes 
and adverse effects of MA regimens, Chen and Creinin (2015) included 20 studies that 
included a total of 33,846 women. All the studies in their review had quantitative designs, 
with four using retrospective cohort analyses and 16 using prospective cohort analyses. In 
their systematic review of the efficacy of different MA protocols, Shaw, Topp, Shaw, and 
Blumenthal (2013) included 29 studies; all were quantitative designs, with nine being 
observational designs.  
In this study, I had one independent variable (i.e., MA protocol, decided by the 
dosing interval) with three levels (i.e., dosing interval of 24 to 36-hours, dosing interval 
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of 6- to 8-hours, and simultaneous dosing). I had two dependent variables, each with two 
levels and three control variables. All three (i.e., gestational age, maternal age, and 
parity) were controlled for when exploring the relationship between the MA protocol and 
the efficacy of the procedure. Only gestational age and maternal age were controlled for 
when exploring the relationship between the protocol and the safety of the procedure.  
Using a retrospective cohort design, I conducted a retrospective analysis of a large 
secondary data set obtained from one of the two largest abortion care providers in the 
United Kingdom. The data from MA clients are captured at multiple centers that are 
operated by one organization across the United Kingdom. All clinics use the same health 
information system. All client data are housed in a common database, which was the 
source of my data set. The database captures over 100 data points for each client, from 
among which, I obtained the data on the independent, dependent, and the control 
variables for any client. If the record of a client was incomplete due to human error in 
entering client information into the health information system, those clients were 
excluded from the study. I analyzed the relationship between the independent variable 
and the dependent variables using regression analysis, which allowed me to control for 
the relevant control variables when analyzing the relationship of the MA protocol to each 
dependent variable. The organization provided me with a de-identified data set with all 
data points that could potentially be used to identify a client removed. This de-
identification was done by the organization, and I did not have access to data with 
identifiers at any point in the process. The de-identification was carried out at the point 
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when the data were transferred from the master database to the Excel format in which I 
received it. 
Definitions 
The following definitions for the safety and efficacy of MAMA is limited to this 
study. While several authors have used these or similar definitions in MA-related 
research (e.g., Gatter et al., 2015; Smith et al., 2014), others have differed in the 
definitions used. As stated by Whitehouse et al. (2017), the process of developing 
universal definitions for these terms is ongoing. 
Abortion: A procedure for terminating a pregnancy (Ganatra et al., 2014). 
Dosing interval: The time gap between the MIFE dose and the first/only MISO 
dose when performing a MA given in hours (Shaw et al., 2013). 
Medical abortion: The induction of abortion using medication alone (Gopal et al., 
2017). 
Medical abortion complication: Receiving an abortion-related diagnosis or 
treatment at any source of care within 6 weeks after an abortion (Upadhyay et al., 2015) 
Medical abortion efficacy: The percentage of women who took a single MIFE 
dose followed, after a dosing interval, by a single MISO dose for a MA that did not 
require a second MISO dose or a vacuum aspiration to complete expulsion (Guest et al., 
2007). 
Medical abortion safety: The percentage of women who took a single MIFE dose 
followed, after a dosing interval, by a single MISO dose for a MA that did not encounter 
complications or side effects that required a clinical consultation (Raymond et al., 2013). 
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Parity: The number of past pregnancies that a woman undergoing a MA has 
carried to term (Ota et al., 2014). 
Unsafe abortion: A procedure for terminating a pregnancy performed by persons 
lacking the necessary skills or in an environment not in conformity with minimal medical 
standards, or both (Ganatra et al., 2014). 
Assumptions 
In my study, I assumed that women who seek first trimester MAs at the clinics 
managed by the organization who provided my data set were representative of all women 
who seek first trimester MAs in the United Kingdom (except for Northern Ireland) in 
terms of their age, their gestational age at seeking an abortion, and their parity. This 
assumption was based on MA being allowed across the United Kingdom (except for 
Northern Ireland) up to 10 weeks and only using MIFE and MISO (see Francome, 2017). 
It was also based on the large size of my data set, increasing the likelihood of women 
representative of those seeking MA in the United Kingdom being captured and the fact 
that the clinics where the data come from being spread widely across the United 
Kingdom (except for Northern Ireland). In interpreting my findings and generalizing 
them to the rest of the world, I assumed that women who seek first trimester MAs in the 
United Kingdom are comparable to such women in other settings in term of their biology. 
I was aware that women seeking MAs in the United Kingdom may differ from those in 
other settings in terms of their age, their gestational age, and their parity; however, these 
variables are controlled for in my analyses.  
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Another assumption was that women in general would find MA protocols that are 
shorter and simpler more attractive if they have acceptable levels of safety and efficacy. 
Levine and Cameron (2009) and Cameron et al. (2010) showed that MA where expulsion 
occurs at home is acceptable to most women, including to women in resource-poor 
settings. Both shorter MA protocols included in my study allow women to complete the 
expulsion at their homes with greater privacy, giving women greater control over the 
timing of abortion and allowing family or friends to provide emotional support. Ho 
(2006), Clark et al. (2007), and Iyengar et al. (2016) showed that women who seek 
abortions find these options attractive. 
The final assumption was that women who receive MIFE and MISO at a clinic 
where my data set comes from and return home contact the abortion provider in the case 
of incomplete expulsion or side effects or complications that require further medical care. 
This assumption was based on the facts that the organization maintains a 24-hour toll-free 
hotline, women who receive an abortion from them receive a unique identifier number 
that allows them to be easily recaptured into the medical information system if they were 
to seek follow-up care, and that any such care is provided free of charge. These facts 
make it highly unlikely that a woman who has significant side-effects, complications, or 
has an incomplete expulsion would contact another provider. All women who seek 
abortion care at the said organization receive pre procedure as well as pre discharge 
counselling. The signs and symptoms of incomplete expulsion as well as of side effects 
and complications that necessitate further care are clearly given to all women. The 
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robustness of these counselling sessions makes it highly likely that women would fail to 
recognize a situation where they must contact the provider again. 
The above three assumptions were critical to this study. The first was critical 
because it allowed the safety and efficacy rates found in the study to be generalized 
across the United Kingdom as well as across settings outside the United Kingdom within 
the maternal age, gestational age, and parity restrictions. The second assumption was 
critical because it allowed MA protocols that have acceptable safety and efficacy levels 
to be interpreted as protocols that women would prefer, allowing the safety and efficacy 
of a given medical protocol to be proxy measures of its attractiveness and acceptance to 
women in all settings. The final assumption was critical because the organization whose 
data I used do not conduct active follow-up appointments with women who return home 
following the MISO dose, assuming instead that the robustness of counselling, the ease 
with which such women can contact them, and the fact that any woman who experiences 
serious side-effects or complications or who need extra procedures to complete expulsion 
receive free care would lead to them contacting the organization in those circumstances. 
Beyond these assumptions, I also assumed the accuracy and reliability of the 
secondary data that my study was based on. Upon receiving the anonymized data set, I 
manually screened the data points relevant to the analyses of each patient, and patients 
whose records were missing one or more data points required for the analyses were 
excluded. However, this process did not capture any inaccuracies in entered data. I 
assumed that key data points, such as the age and parity of each woman, the gestational 
age at their presentation to the clinic, and the information given on the MA protocol 
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received, are accurate. Furthermore, if an identifier number of a given MA recipient did 
not appear among the identifiers of women who had a second contact with the clinic 
network due to a complication, adverse event, or due to incomplete expulsion, I assumed 
that they had a safe and efficacious procedure according to the variable definitions. 
Scope and Delimitations 
In my study, I compared the efficacy and the safety of MAs in women with 
gestational ages below 10 weeks. The length of the MA procedure was used as the single 
independent variable of the study. Cost, level of pain, and the length of bleeding were 
other factors that have been studied in past abortion research (Bracken et al., 2014; Fiala 
et al., 2014; Lo & Ho, 2015). I chose the topics of efficacy and safety for this study 
because they are the two parameters that regulatory bodies mostly consider when 
approving new abortion procedures (see Ganatra et al., 2014). Other factors such as cost, 
pain, and bleeding period relate more to the acceptability of an abortion procedure by 
women (Louie, et al., 2014; Swica et al., 2013). While important, these factors were left 
out due to my focus on comparing the efficacy and the safety of the different MA 
protocols in this study. 
This study has a high generalizability to women seeking MAs using the protocols 
studied prior to completing the 10th week of gestation. The generalizability is limited to 
women seeking a MA at one of the United Kingdom’s largest abortion providers. The 
subjects are likely to be British (while any woman who walks into a clinic can obtain a 
procedure) and likely to be registered with the National Health Service (i.e., most of the 
British population) because a procedure costs a nonregistered woman approximately 
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U$500. Nonregistered women who paid for the procedure fee were included in the 
sample frame. Despite being limited to (mostly) British women who are (mostly) 
registered with the National Health Service, the specific gestational age limits and the 
specific MA protocols support generalizing the findings to MAs below 10 weeks using 
these exact protocols in settings outside of the United Kingdom. The professional 
standards of UK abortion providers (Chamberlain, 2017; Rubin, 2014) is unlikely to limit 
generalizability to settings where a MA is carried out by lower level providers because 
MAs carried out by them have been shown to be safe (Løkeland et al., 2014; WHO, 
2015). 
I considered positivism and empiricism as standalone theories for this study. 
Positivism was a suitable framework for the linear, uni-directional, flow of my study 
design (see Theory of Knowledge, 2015). Manjikian (2013) demonstrated that positivism 
suits studies where observations are analyzed, hypotheses tested, and conclusions 
reached.  Hjørland (2005) and Theory of Knowledge (2015) showed positivism to be 
suitable for quantitative study models; however, the room afforded by postpositivism to 
introduce subjective interpretation of analyses was critical to summarizing the findings of 
this study, allowing me to focus not simply on how the efficacy and safety of the three 
MA protocols compare to one another but also consider the benefits given to women by 
the shorted protocols. I also considered empiricism as a standalone framework. Hjørland 
(2005) demonstrated similarities between empiricism and today’s positivism and showed 
how theoreticians see experienced or observed data as the only way of acquiring 
knowledge.  My ultimate choice of theoretical framework was a postpositivist approach 
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that places empirical studies in a broader framework based on a contextual understanding 
of social inquiry (see Fischer, 1998). 
Limitations 
Cohort designs are suitable when describing subgroups within a population with 
respect to an outcome and a set of risk factors (Levin, 2006). Past studies have showed 
the likelihood of MA failure and MA complications to be very low with MIFE and MISO 
combinations (WHO, 2015). This made a cross-sectional design with a large sample size 
a practical choice. A retrospective design allows larger sample sizes for each protocol, 
thereby increasing power and narrowing the confidence intervals. Cohort designs suit 
studies that describe patterns of relationships between variables (Frankfort-Nachmias & 
Nachmias, 2008). Such a design was appropriate for this study because I developed the 
research questions to address the correlation between MA protocols and the safety and 
the efficacy of the resulting procedures instead of proving a causality. The other benefits 
of using a retrospective cohort are the low financial and temporal cost, the ability for the 
analysis to include multiple control variables, and having no risk of loss to follow up 
(Levin, 2006; Sedgwick, 2014).  
Using an observational study design instead of an experimental design with 
randomization was a major limitation of my study. Observational studies are less rigorous 
than true experiments with randomization (Creswell, 2013). The design used in this study 
does not allow an experimental approach where the independent variable(s) can be 
manipulated to observe the effect(s) of such manipulation on the dependent variables (see 
Frankfort-Nachmias & Nachmias, 2008). The design does not exclude the likelihood of 
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either MA failure or complications arising due to factors other than the protocol used, 
although this was minimized by controlling for several control variables. My use of real-
life data, not data collected for research under research rigor was another limitation. The 
accuracy of the records included in the analyses was maximized, however, by my review 
of each client record to check for completeness. The large sample size that represents the 
UK population included in my study improves the generalizability despite the design 
used (see Levin, 2006). 
I considered both experimental and quasi-experimental, prospective, quantitative 
designs for this study. Prospective designs (either experimental or quasi-experimental) 
that could answer the two research questions with an adequate sample size were rejected 
due to logistical, financial, and time constraints (see Creswell, 2013). Given that the 
failure of MAs is lower than 5% when MIFE and MISO combinations are used (WHO, 
2015), capturing a significant number of failures in the three MA protocol groups would 
require a long prospective, follow-up period (see Creswell, 2013). A full experimental 
design was also unfeasible due to randomizing women into one of the three MA protocols 
without giving consideration to the choice of the individuals raising significant ethical 
challenges. While a prospective design could lead to more robust data being gathered 
(Frankfort-Nachmias & Nachmias, 2008), it would have required dedicated data gatherers 
and training of the clinical staff that enters patient data into the information system to 
achieve that higher data quality. An experimental design would be more resource 
intensive compared to a quasi-experimental design (Creswell, 2013; Frankfort-Nachmias 
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& Nachmias, 2008), and the selected retrospective cohort analysis design is less resource 
intensive than both of the previously mentioned designs. 
Significance of the Study 
The body of literature on MA is wrought with gaps. My exhaustive literature 
review discovered 13 published studies that included short-protocol studies. None of 
those studies simultaneously compared more than two protocols, and none compared the 
6- to 8-hour dosing interval with simultaneous dosing. Both the 6- to 8-hour dosing 
interval and the simultaneous MIFE and MISO dosing have the potential to shorten the 
MA process, potentially allowing women to complete their MA at home. Homebased 
MAs could improve women’s acceptability by allowing greater privacy, giving women 
greater control over the timing of the process, and allowing family or friends to provide 
emotional support (Clark et al., 2007; Ho, 2006). Taking MISO at home has also been 
shown to be acceptable to women in resource-poor settings (Iyengar et al., 2016; Louie, 
et al., 2014). Past MA literature also lacks studies that undertook secondary analyses of 
real MA patient data of any short MA protocol. No researcher studying a MA protocol 
with a dosing interval less than a day has analyzed a retrospective data set. Each of the 13 
short MA protocol studies that have been published so far were prospective. Efficacy and 
safety analyses using a large, retrospective data set where the women underwent a MA 
outside of a research setting could uncover efficacy differences between these protocols 
administered in a research setting versus in day-to-day clinical practice.  
The results of this study could also fill a gap in the literature concerning 6- to 8-
hour and simultaneous dosing conducted in the United Kingdom. Only one study that 
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explored the 6-to 8-hour dosing interval (Guest et al., 2007) and one that explored the 
simultaneous dosing protocol (Lohr et al., 2007) has been published in the United 
Kingdom. Both studies had small sample sizes, with Guest et al. (2007) having 215 
women and Lohr et al. (2007) having 120 women in total. The United Kingdom differs 
from many countries with liberal abortion legislature in not allowing home administration 
of MISO (Francome, 2017). Demonstrating that the 6-to 8-hour dosing interval protocol 
or the simultaneous dosing protocol has acceptable safety and efficacy would be of great 
value to women and healthcare providers in the United Kingdom. Such findings could 
potentially lead to a MA protocol change or expansion in the United Kingdom. Such a 
change in the United Kingdom could potentially have a cascading effect on the MA 
protocols used in other commonwealth countries and bring these protocols to the notice 
of organizations such as the WHO, United Nations Population Fund, International 
Federation of Gynecology and Obstetrics, and the Royal College of Obstetrics and 
Gynecology. 
These organizations guide reproductive health practices across the globe. Hence, 
policy and guideline changes in these institutions would lead to a change in the way MA 
is practiced across the world. If they become the global norm, these shortened MA 
protocols could bring safe, first trimester MAs that are completed at home within the 
reach of millions of women across the globe. The public health and social implications 
that these changes could lead to further augment the significance of my study.  
Half of the approximately 50 million annual abortions in the world are unsafe 
(Sedgh et al., 2014; Vrachnis et al., 2016). These unsafe abortions produce an estimated 
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4.7% to 15% of the approximately 300,000 global annual maternal deaths (Filippi et al., 
2016). MA is safer, cheaper, and less medicalized compared to surgical abortion 
(Simmonds et al., 2017; Zane et al., 2015). The shorter MA protocols that I might 
demonstrate to be alternatives to the current lengthy protocols can persuade more women 
to choose MA instead of surgical abortion. MA becoming a 1-day process could also 
entice more clinics, hospitals, and practitioners to offer it. Both of these changes can 
increase access to safer abortions for women across the world, and in turn, reducing the 
morbidity and mortality that is seen today due to unsafe abortions. Healthcare systems 
and governments could save resources that are currently spent both for providing more 
expensive surgical abortions as well as for managing complications from unsafe 
abortions due to MAs becoming commoner and more acceptable to women. With MIFE 
registered in 57 countries (Dunn & Cook, 2014) and MISO registered in over 100 
countries (Medication Abortion, 2016), a 1-day MA protocol that uses these two drugs 
could give millions of women access to safer abortions and prevent many surgical 
abortions due to women opting for the (now) fast and efficient MA option. 
Summary and Transition 
MA is rapidly growing in popularity among the approximately 40 million women 
who seek an abortion each year (Gopal, Ganamurali, & Kumari, 2017; Grossman & 
Goldstone, 2015). A growing percentage of those 40 million women who might have 
resorted to unsafe surgical abortion are now turning to safer medical options for their 
termination (Sedgh et al., 2014; Vrachnis et al., 2016). The length of the MA procedure, 
which is predominantly dictated by the dosing interval between MIFE and MISO, 
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remains a key barrier to MA becoming a shorter and simpler process that women could 
complete at home in relative comfort. The literature on MA has notable gaps with regards 
to explorations of protocols that are shorter and simpler than the present norm. In this 
study, I compared the efficacy and the safety of two MA protocols with dosing intervals 
shorter than a day to the conventional protocol and to each other. If one or both shorter 
MA protocols was shown to have acceptable efficacy and safety, they could potentially 
replace the lengthier conventional protocol, making MA a shorter and simpler procedure 
that many more millions of women find acceptable. 
In Chapter 1, I highlighted the public health importance of shorter, simpler, MA 
protocols and outlined the gap that I aimed to fill in the field of MA research. In the 
chapter, I presented a brief background, the problem statement, and its purpose. Chapter 
1 also included a presentation of the research questions and the hypotheses along with the 
variables of the study. The theories used to guide this study and form its theoretical 
foundation were outlined. Definitions of the different terms related to MA that I used in 
the study were also presented. Additionally, the nature of the study was presented, along 
with its assumptions and limitations and its significance from the perspectives of public 
health and social change. 
In Chapter 2, I will provide a broader background on MA and the drive to 
simplify and shorten MA. In the chapter, I will present the literature review and the 
analysis done on existing research to find the gap that I attempted to fill with this study. I 
will also outline the research question, hypotheses, the problem statement, and the 
objectives of my study. I will also compare MA literature in the chapter, giving specific 
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focus to studies conducted on MA protocols with a dosing interval of less than 12 hours. 
Chapter 2 will also include a broader account of the theoretical framework of my study 




Chapter 2: Literature Review 
Restating the Problem 
Devereux (1954, p. 98) stated that “Abortion is an absolutely universal 
phenomenon, and it is impossible to imagine a social system in which no woman would 
ever feel at least compelled to abort”. Despite centuries of debate over the morality, 
legality, and the ethics of abortion and irrespective of whether abortion was outlawed 
where they lived, women have terminated undesired pregnancies (Dellapenna, 2006). 
Hippocrates instructed women who wished an abortion to jump repeatedly, touching their 
buttocks with their heels (Fant & Lefkowitz, 1992). The New York Times estimated that 
200 abortionists were active in New York in the 1870s (Gordon, 1976). Women have 
used primitive practices, such as weightlifting, strenuous labor, fasting, irritant leaves, 
and bloodletting, to induce abortions (Devereux, 1967). Thyme, worm fern roots, and 
other infusions have been used to induce abortions since the time of Nero (Gordon, 
1976). More recently, the ingestion of turpentine, ammonia, mustard, and other 
substances have been used to induce abortions (Devereux, 1967; Gordon, 1976). 
The WHO (1992) defined a maternal death as “the death of a woman whilst 
pregnant or within 42 days of delivery or termination of pregnancy, from any cause 
related to, or aggravated by pregnancy or its management, but excluding deaths from 
incidental or accidental causes” (section 15). Unsafe abortion is a “procedure for 
terminating an unintended pregnancy either by people lacking the necessary professional 
skills or in an environment lacking the minimal medical standards, or both” (WHO, 2011, 
p. 5). In 2012, there were 213 million pregnancies in world, with 85 million being 
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unintended and over 40 million of the unintended pregnancies being aborted (CITE). 
Over half of the 40 million abortions were carried out in an unsafe manner (Sedgh et al., 
2014; Vrachnis et al., 2016). In 2015, there were 303,000 maternal deaths in the world, 
with unsafe abortion causing an estimated 4.7% to 15% of them (Filippi et al., 2016; 
Kassebaum et al., 2014).  
The induction methods used for abortion in the last 3 decades can be classified as 
either surgical or medical. Curettage, invented in 1844, was the first widely used surgical 
method despite its high complication risks (Wu & Wu, 1958).  Wu and Wu (1958) 
designed the first electric vacuum aspiration in 1958 (Coombes, 2008), and this was the 
primary method of inducing abortion in the 1960s (Li, Lee, & Wang, 2017).  In the 
1970s, manual vacuum aspiration was developed by Karman with the aim of replacing 
the risky curettage in low resource settings (Potts, 2010). With prostaglandins, such as 
MISO, becoming available in the early 1970s and anti-progesterones, such as MIFE in 
the 1980s, MA, the induction of abortion using medication alone (Gopal, et al., 2017), 
became an alternative to vacuum aspiration (Kulier et al., 2004). MIFE in conjunction 
with a prostaglandin is effective for early pregnancy termination (Urquhart et al., 1997), 
and MA quickly became a popular alternative to surgical abortion (Gatter et al.; Ngo et 
al., 2011) 
Clinically, first trimester, legal abortion carries much less risk compared to 
childbirth; Raymond and Grimes (2012) showed that the mortality risk associated with 
childbirth is approximately 14 times higher than that with legal, first trimester abortion. 
The authors also showed that the overall morbidity associated with childbirth greatly 
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exceeds that with legal, first trimester abortion. Berer (2017) showed that abortion is 
safer when it is available on request, is affordable, and accessible. Hence, any woman 
who carries an unintended pregnancy to term due to her inability to access a safe abortion 
is being forced to putting her health and safety at risk. Even in contexts where abortion is 
legally allowed, requiring high-level clinicians or surgeons to provide the service and 
limiting abortion provision to high-level care facilities blocks women’s access to safe 
abortion services (WHO, 2012). These facts demonstrate the need for addressing what 
developments could make abortion cheaper, simpler, and remove provider type related 
barriers that limit access to safe abortion. 
Study Purpose 
In this study, I compared the efficacy and the safety of three MA protocols. The 
first uses the conventional 24- to 36-hour dosing interval between the drugs. The second 
uses a 6-hour dosing interval between the drugs, while in the third, the two drugs are 
administered simultaneously. I used a retrospective cohort analysis of a large secondary 
data set of MA patients in this comparison. Efficacy of a protocol was measured by the 
percentage of women who had a MA using the said protocol that required either an 
additional abortifacient dose or a vacuum aspiration to complete the procedure. Safety of 
a given MA protocol was measured by the percentage of women who had a MA using the 
said protocol that experienced a complication that required clinical care. 
Concise Synopsis of the Literature Review Findings 
Current, safe, abortion induction is carried out using several surgical and medical 
protocols (Gaudineau, Agostini, & Vayssière, 2016; Morris et al., 2017). WHO (2012) 
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and Gaudineau et al. (2016) recommended manual and electric vacuum aspiration for 
surgical abortion up to 14 weeks and combinations of MIFE and MISO (exact protocols 
varying with gestational age) for MA. MA allows safe, cheaper, abortion services in de-
medicalized settings (Raymond et al., 2013; Simmonds et al., 2017; Zane, et al., 2015). 
Women can complete a MA at home without follow up at a health facility (Mählck & 
Bäckström, 2017). Women who wish to avoid surgery or anaesthesia value having a 
choice of abortion method (Hamoda & Templeton, 2010). MA should be routinely 
available to women, and it is the best option for improving safe abortion access for 
women (Hamoda & Templeton, 2010; Orrantia & Armand, 2017). 
Although prostaglandins other than MISO can be used with MIFE, due to lower 
incidences and severity of side effects and lower costs, MISO is the preferred 
prostaglandin option (Sang, 1999; WHO, 2010). While MISO alone in different dosages 
can be used to induce abortion at different gestational ages, it is always inferior to MIFE 
and MISO combinations (WHO, 2012). Regimens of MIFE followed by a dosing interval 
by MISO is the norm for MA (Gatter et al., 2015; Raymond, et al., 2013). This time gap 
has remained at 24 hours or more over the last 2 decades (Creinin et al., 2004; WHO, 
2015), making MA a much longer process than surgical abortion. Furthermore, many 
countries do not allow the self-use of either drug (Gatter et al., 2015). Due to these 
reasons, women who want to have a MA are forced to stay in a health facility for over a 
day, make two or more visits, or take one or both drugs and complete the expulsion with 
no clinical supervision (Aiken et al., 2017). 
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Starting with studies of MIFE in combination with varying prostaglandin 
analogues (Baulieu, 1985; Yan, 1983), many aspects of different MA protocols at various 
gestational ages have been studied over the past 3 decades. MA research has sought the 
best prostaglandin analogue to be coupled with MIFE (Avrech et al., 1991; Swahn & 
Bygdeman, 1989), the most efficacious dosages of MIFE and MISO (Creinin, 2000; 
McKinley, Thong, & Baird, 1993), and the best routes of MISO administration (Aubeny 
& Chatellier, 2000; Newhall & Winikoff, 2000). The most efficacious doses being 
broadly established as 200mg of MIFE with 800 µg of MISO (Raymond et al., 2013), 
MA research has also assessed the feasibility of MA completed or fully conducted at 
home (Constant et al., 2017; Purcell et al., 2017) and lighter-touch approaches of 
following-up with women who had MA (Anger, et al., 2017; Chen et al., 2016) and 
expanded into shortening the length of the MA process by shortening the dosing interval. 
However, only 13 studies have been conducted with researchers exploring MA protocols 
with dosing intervals below 12 hours. The first (i.e., Pymar et al., 2001) as well as others 
(i.e., Creinin et al., 2004) have showed comparable efficacy between MIFE 200 mg, 
followed 6 to 8 hours later by MISO 800 μg vaginally and the conventional protocol (i.e., 
24- to 36-hour dosing interval) at gestational ages below 49 days. Fox et al. (2002) and 
Guest et al. (2007) showed that the 6- to 8-hour dosing interval for MA up to 63 days of 
gestation provides acceptable efficacy. Creinin et al. (2004), authors of the first 
randomized trial, also showed comparable efficacy between the 6- to 8-hour dosing 
interval and the conventional protocol. Protocols with simultaneous dosing at gestational 
ages up to 49 days (Li et al., 2006; Li et al., 2011; Murthy et al., 2005), 56 days (Kapp et 
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al., 2006), and 63 days (Creinin et al., 2007; Schreiber et al.; Verma, et al., 2017) have 
been shown to have expulsion rates of approximately 90%. Only Lohr et al. (2007) 
showed simultaneous dosing to have expulsion rates below 80% at all gestational ages 
(below 49 days, 50–56 days, and 57–63 days). 
Outline of the Chapter 
In this chapter, I will outline the literature review conducted related to the clinical 
areas related to the study as well as to the theoretical frameworks that underpins it. 
Literature findings on multiple aspects of abortion provision will be presented with a 
strong focus on MA. The evolution of current abortion will be reviewed, focusing briefly 
on the evolution of current surgical methods and the inception of MA. How the 
introduction of MA affected the abortion care landscape with regards to women’s 
preference of method, women having a choice between two approaches (i.e., medical 
versus surgical), and how access to safe abortion increased will be outlined. I will review 
past research into the ideal dosing of MIFE and MISO as well as research into the best 
route of MISO administration. Research in to reducing the length of the MA process by 
reducing the dosing interval between the MIFE and MISO will be exhaustively reviewed. 
Through this, I will outline the journey from a 36- to 48-hour dosing interval to the 6- to 
8-hour dosing interval and to complete removal of the dosing interval (i.e., simultaneous 
MIFE and MISO dosing). I will present the key research gaps found in studies of shorter, 
simpler MA protocols. In this chapter, I will also present past findings on abortion, 
including an exhaustive review of past studies conducted in attempts to reduce the dosing 
interval between MIFE and MISO in early MA. A review of the literature around the key 
33 
 
variables and a summary will also be provided. Finally, an account of postpositivism and 
empiricism, the theoretical frameworks that underpinned this study will be presented. 
Brief accounts of the evolution of postpositivism and empiricism and the links between is 
the two will be provided. The use of postpositivism and empiricism in studies like mine 
in the past and the suitability of these theories as the theoretical frameworks for this study 
will be demonstrated. 
Literature Search Strategy 
I conducted the literature review for this study through searching multiple, peer-
reviewed, scholarly articles from reputable databases. The databases searched were 
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINHAL), Medline 
with Full Text, Health and Medical Complete (ProQuest), and the Cochrane Database of 
Literature reviews. The search terms used were medical abortion, pregnancy termination, 
mifepristone + abortion, mifepristone + termination, misoprostol + abortion, and 
misoprostol + termination. I limited the search to these databases because adding more 
databases resulted in search result overlap rather than new findings. Articles going back 
to 30 years were screened to capture important knowledge on the inception of MA; 
however, my review of evidence related to the simplification and shortening the MA 
process focused on evidence from the last 15 years, with a heavy focus on evidence 
published in the last 5 years. I reviewed 813 articles, with 260 published in or after 2012. 
Literature was searched for multiple aspects of abortion, with a stronger focus on 
MA. The evolution of current abortion was reviewed, focusing briefly on the evolution of 
current surgical methods and the inception of MA were explored. The effect of MA with 
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regards to women’s preference of method, women having a choice between two 
approaches (medical versus surgical), and how access to safe abortion increased due to 
MA was explored. Research into finding the ideal dosing of the two abortifacient 
medications MIFE and MISO were explored, as well as research into the best route of 
MISO administration. The greatest focus of the literature review was focused on research 
that explored ways to reduce the length of the MA process by reducing the dosing 
interval between the MIFE and MISO. Through the review of literature on reducing the 
dosing interval, the journey from a 36- to 48- hour to the 6- to 8- hour dosing interval and 
to complete removal of the dosing interval (simultaneous dosing) was outlined 
Variations in Global MA Practice 
With MISO becoming available since the early 1970s and MIFE being available 
since the 1980s, various MA protocols that use these in conjunction have been used for 
early pregnancy termination (Urquhart et al., 1997). Currently, MIFE is registered in 57 
countries (Dunn & Cook, 2014) and MISO in over 100 (Medication Abortion, 2016). MA 
using MIFE and MISO combinations is allowed in all countries where MIFE is 
registered. This includes most European countries with a few exceptions such as Malta, 
Ireland, Poland, Czech Republic, and Slovakia (Medication Abortion, 2016). The list of 
countries where MA using MIFE and MISO combinations is allowed also includes low 
and middle-income countries such as India, Nepal, Bangladesh, Ethiopia, Vietnam, and 
Ghana (Medication Abortion, 2016). However, the indications for which an abortion is 
allowed, and the intricacies of what is allowed and prohibited when providing a MA 
differs greatly among these 57 countries. 
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For example, England and Wales does not allow either MIFE or MISO to be 
taken outside of a health facility, while in Scotland, prescribed MISO can be taken by 
women at home (Regan & Glasier, 2017). India and Nepal have laws that are less 
restrictive than many European countries, allowing both MIFE and MISO to be obtained 
from pharmacies with a prescription (Powell-Jackson et al., 2015). This is also the case in 
Australia (Grossman & Goldstone, 2015). Bangladesh, a colourful example of the variety 
seen in legal MA, allows on demand termination of pregnancies using MIFE and MISO 
up to 10 weeks of gestation but under the medical term menstrual regulation (Singh, et 
al., 2017). In countries with MIFE and MISO allowed but have restrictions on home use 
and use of either drug without direct medical supervision, those restrictions are based on 
a lack of confidence in the safety and efficacy of MAs carried out using the combination 
(Regan & Glasier, 2017). 
Key Variables 
The Efficacy and Safety of Medical Abortion 
Reaching a consensus regarding how MA safety and efficacy should be measured 
has been challenging (Whitehouse et al., 2017). This difficulty extends into measures of 
abortion outcomes in clinical trials, with selecting and reporting on outcomes across trials 
showing a large variation (Creinin & Chen, 2016). Under the Core Outcome Measures in 
Effectiveness Trials (COMET) Initiative (2017), doctors Whitehouse and Gulmezogluthe 
of the WHO are in the process of developing a core outcome set for induced abortion. 
Until those are published, The MA Reporting of Efficacy (MARE) guidelines (Creinin & 
Chen, 2016) represents the only guidance available to streamline abortion outcomes for 
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efficacy. The authors recommended that MA failure must be clearly defined (e.g., 
ongoing pregnancy, incomplete abortion, and participant symptoms).   
Routine follow-up visits are not needed for women who undergo MA using MIFE 
and MISO (Mählck & Bäckström, 2017; WHO, 2012). Less than 5% of them require 
surgical intervention to resolve incomplete abortions, continuing pregnancies, or bleeding 
(Gopal et. Al., 2017). Pain is the main side effect, and in most cases, simple analgesics 
easily manage the pain of MA (Cavet, Fiala, Scemama, & Partouche, 2017). Other side 
effects (diarrhoea, fever, and abdominal pain) rarely reach a severity that require facility 
care (Lo & Ho, 2015; Nijman et al, 2017). In defining MA efficacy, my study considered 
both an ongoing pregnancy and an incomplete abortion as failures (Gatter et al., 2015; 
Gopal et al., 2017). Complications and severe adverse events defined MA safety, with the 
percentage of women who had a MA using a given protocol and did not experience 
symptoms that needed further health facility care being used as the indicator of the 
protocol’s safety (Gatter, et al., 2015; Sanhueza, et al., 2014). 
Abortifacient Dosing Interval and the Route of MISO Administration 
The recent Medical Abortion Reporting Efficacy (MARE) guidelines (Creinin & 
Chen, 2016) and Standardizing Abortion Research Outcomes (STAR) initiatives 
(Whitehouse et al., 2017) outlined how abortifacient exposure should be presented in 
abortion research. Both dictated that the drugs used, their dosage(s), the dosing interval in 
hours, and route(s) of administration must be given. Many researchers have explored 
varying dosages and routes of administering MIFE and MISO (Meena, 2016; Tsereteli et 
al., 2016; Sheldon et al., 2017). The dosages of both have varied continuously, with 
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researchers seeking the dosages of both drugs that provide the best balance between 
efficacy of the MA procedure and not exposing women to unnecessary dosages, and 
hence to more side effects. Many countries’ standard dosage for MIFE in first trimester 
abortion was initially set at 600mg (Raymond et al., 2013). However, recent study 
findings have resulted in the standard MIFE dose to be reduced to 200mg (Faundes, 
2011; RCOG, 2011; WHO, 2012).  
Irrespective of gestational age, MIFE is always administered orally (WHO, 2012). 
The best route of MISO administration however, has been the focus of many researchers. 
WHO (2012) recommended four routes of MISO administration (vaginal, buccal, 
sublingual or oral) for pregnancies less than 9 weeks (63 days). The MISO dosages 
recommended are 800 μg for vaginal, buccal, and sublingual routes and 400 μg for the 
oral route. Oral MISO has lower MA efficacy compared to the vaginal, buccal, and 
sublingual routes (Raymond et al., 2013) and is therefore not recommended for 
gestational ages over 7 weeks (WHO, 2012). All patients included in my study received 
MISO through the buccal route. The evidence on MA efficacy based on the route of 
MISO played a critical role when analyzing the efficacy of the different MA protocols in 
my study and when assessing the suitability of those protocols to be considered as viable 
alternatives to existing protocols.  
Apart from the dose and the route of MISO, the key variable in MA protocols is 
the gap (dosing interval) between the MIFE and the MISO. From the decade-old U.S. 
Food and Drug Administration approved dosing interval of 48 hours (Pyeron, et al., 1993; 
Spitz, et al, 1998) to the WHO (2012) recommended 24- to 36- hour dosing interval, and 
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to the more recently studied dosing intervals of 6- to 8- hours (Creinin, et al., 2004; Guest 
et al., 2007), 2 hours (Tendlar et al., 2015), and zero hours (Creinin et al., 2007; Li et al., 
2011; Verma et al., 2017), many authors have shown the efficacy of MA to vary with the 
dosing interval. This is outlined in detail below and forms the foundation of the 
relationships that I explored in my study.   
The Inter-Relationships of the Study Variables 
Both dependent variables of this study (efficacy and safety) are affected by 
service providers’ competency (Pawde, Ambadkar, & Chauhan, 2016). The United 
Kingdom is one of the world’s most regulated clinical systems. Considering the 
regulations that govern service providers’ licensure and routine competency 
(Chamberlain, 2017; Rubin, 2014), it can safely be assumed that the MAs of the study 
subjects were conducted by competent providers (Care Quality Commission, 2012). The 
standards were further elevated by the Care Quality Commission (2016), introducing 
stringent standards specific to abortion services and abortion providers. The independent 
variable of this study is the MA protocol. Any protocol used in MA has three 
contributors. They are the dosage of MIFE or MISO; the dosing interval between MIFE 
and MISO; and the route of MISO (oral, vaginal, buccal/sublingual). Up to 63 days’ 
gestation, the relationships among the variables of this study is as follows. Changing the 
dosage of MIFE or MISO or both changes the efficacy of MA (Soon, Costescu, & 
Guilbert, 2016). Changing the dosing interval between MIFE and MISO also affects the 
efficacy of MA (Tendler et al., 2015). MIFE is always given orally. Changing the route 
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of MISO also affects the efficacy of MA (Bhattacharjee et al., 2008; Shannon et al., 
2006; Tang, Danielsson, & Ho, 2007).  
Due to variations in how studies define the efficacy of MA, it’s important to keep 
in mind that the means used to verify the efficacy of treatment have a strong influence on 
the results (Haimov-Kochman et al., 2008). The efficacy and the safety of a given MA 
protocol is affected by certain variables. Efficacy is affected by the gestational age of the 
pregnancy, the parity of the mother, and the number of past abortions (Cotte, Monniez, & 
Norel, 2008; Lefebvre et al., 2008; Thiebaut et al., 2017; WHO, 2012). Safety is affected 
by the gestational age (Lefebvre et al., 2008; Raymond et al., 2013; Thiebaut et al., 2017; 
Zane et al., 2015). 
 
Figure 1. Relationships among key variables.  
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Evidence suggest that MA safety is not affected by the number of past 
pregnancies or the number of past abortions (Ashok et al., 2002; Lefebvre et al., 2008). It 
is important to keep in mind the obvious, strong, relationship between maternal age and 
parity. As most of the authors did not assess the effect of parity and maternal age on MA 
safety separately, it is difficult to determine if both affect its safety. The relationships 
among the independent, dependent, and the covariables of the study are portrayed in 
Figure 1. 
Evolution of the Reduced Dosing Interval 
The dosing interval between MIFE and MISO has remained over 24 hours for 
several decades (WHO, 2015). Pymar et. Al. (2001) were the first to study a protocol 
with a dosing interval less than 12 hours, and where MA could be a 1-day process. The 
authors showed that the efficacy of MIFE 200 mg, followed 6- to 8- hours later by MISO 
800 μg vaginally in women with gestational ages below 49 days was comparable to the 
convention protocol with a 36- to 48- hour dosing interval. Fox et. Al., (2002) showed 
that the same short protocol had comparable expulsion rates and side effect rates to the 
conventional protocol in women with gestational ages between 50 and 63 days. Guest et 
al. (2007) reproduced these results. Creinin et al. (2004) showed that the same protocol is 
comparable to a protocol where the dosing interval was 24 hours at gestational ages up to 
63 days. 
Murthy et. al., (2005) were the first to study a protocol where MIFE and MISO 
were given simultaneously. They showed that simultaneous oral MIFE 200 mg and 800 
μg vaginal MISO produced expulsion rates of 90% (95% CI 80% - 99%) at 24h when the 
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gestational age was below 49 days. Schreiber et. al., (2005) showed that the same 
protocol has 24-hour expulsion rates of 88% (95% CI, 77% - 98%) at gestations between 
50 and 56 days and expulsion rates of 83% (95% CI, 77% - 94%) at gestations between 
57 and 63 days. Kapp et. al., (2006), studying the efficacy of a simultaneous protocol 
where the MIFE dosage was reduced to 100mg showed a similar expulsion rate to 
Schreiber, et al. (2005) in women with gestational ages below 56 days. Li et al. (2006), 
reproduced the results of Murthy et al. (2005a) and Creinin et al. (2007) reproduced the 
results of Schreiber et al. (2005b) in a randomized, noninferiority trial with a control 
group using a protocol with a dosing interval of 24 hours. 
Studying a simultaneous dosing protocol of MIFE 200 mg and MISO 600 μg for 
gestational age limits up to 49 days, Li et al. (2011) showed the protocol to have 
complete expulsion rates of 92.6%. Verma et al. (2017) studied a simultaneous dosing 
protocol with the MISO dose reduced to 400 μg. Comparing its efficacy in women with 
gestational ages below 63 days to the efficacy of the conventional protocol (dosing 
interval of 36- to 48- hours), the authors showed the simultaneous protocol to have an 
expulsion rate of 96% (95% CI 95.1-98.2%) compared to 95% (95% CI 93.0-96.8%) for 
the conventional protocol. The only study where a simultaneous protocol had expulsion 
rates of below 80% in the first trimester was Lohr et al. (2007). However, in the 
simultaneous protocol used by the authors, the MISO 800 μg was administered using the 
buccal route (not the vaginal route as in all other studies of simultaneous protocols). The 
expulsion rates shown by the authors were 73% (95% CI 56% - 85%) at gestations below 
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49 days, 69% (95% CI 52% - 83%) at gestations between 50 and 56 days, and 73% (95% 
CI 56% -85%) at gestations between 57 and 63 days). 
Multiple authors of pharmacokinetic studies of MISO that compared oral and 
vaginal administration have shown that vaginal misoprostol results in slower absorption, 
lower peak plasma levels, but slower clearance. This gives a result similar to an 
extended-release MISO preparation (Danielsson et al., 1999; Khan et al., 2004; Ziemann 
et al., 1997). MISO administered vaginally also results in a greater overall exposure to 
MISO, augmenting the drug’s effects on the cervix and uterus (Danielsson et al., 1999). 
The superior results produced by vaginal MISO is the likely cause of Lohr et al. (2007) 
observing poor outcomes with their simultaneous dosing protocol that used buccal MISO 
compared to the other six sets of authors, all of whom used simultaneous protocols that 
administered MISO using the vaginal route. There is a case for trying to avoid 
administering MISO vaginally, as authors (Arvidsson, Hellborg, & Gemzell-Danielsson, 
2005; Schaff, Fielding & Westhoff, 2001) have shown that women prefer oral, buccal, or 
sublingual routes to the vaginal route. 
A closer exploration of studies that examined dosing intervals (and hence a 
shorter MA process) of less than 12 hours is of value. In doing so, attention should be 
paid to the dosages of MIFE and MISO and the routes of MISO used in these studies. The 
findings in this section show that the protocol with a 6- to 8- hour dosing interval and 
simultaneous dosing shows promise as alternatives to the conventional protocol. These 
two protocols could potentially make most MAs a single-day process. Both protocols 
have been shown to carry safety and efficacy levels that are either equal to, or near to 
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those of the conventional protocol. Seeking out and reducing gaps in literature on these 
two protocols could strengthen the case for healthcare systems and countries adopting 
these protocols as their first-line MA protocol or as viable alternatives to be offered 
alongside the conventional protocol. In my study, I analyzed a data set that is larger than 
any previous study. I also present efficacy and safety analyses based, for the first time, on 
a large, retrospective data set where the women underwent MA outside of a research 
setting. 
Gaps in the Literature and Their Significance 
Gaps are found in the large body of literature on MA. In my literature review, I 
could not discover any study that simultaneously compared more than two protocols. I 
also failed to discover any study that compared the 6- to 8- hour dosing interval with 
simultaneous dosing. None of the authors in the 13 short-protocol studies pointed out 
these areas as requiring further research. In many countries without restrictive abortion 
laws, MISO can be prescribed to be taken at home (Berer, 2017), meaning that women 
must visit a doctor only once for a MA prior to a gestational age of 63 days. Evidence 
suggests that women prefer the completion of MA at home. One in four women 
requesting abortions at the Royal Infirmary of Edinburgh preferred home MA if it was 
available (Levine & Cameron, 2009). Cameron, et al. (2010) showed 79% of women who 
had first trimester MAs at home would recommend it to a friend. Homebased MA may 
improve its acceptability by allowing greater privacy, giving women greater control over 
the timing of abortion, and allowing family or friends to provide emotional support 
(Clark et al., 2007; Ho, 2006). Women taking the MISO at home is less burdensome for 
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health care providers (Lie, Robson, & May, 2008) and acceptable to most women, 
including in resource poor settings (Iyengar et al., 2016; Louie et al., 2014). Whether MA 
where the second stage is completed at home is as effective as clinic-based protocols is 
unclear (Ngo et al., 2011).  
The other significant gap is in secondary analyses of MA patient data of any short 
MA protocol in any setting. During my literature review, I did not find a single study that 
analyzed a retrospective data set. All thirteen published studies on such protocols are 
prospective studies, where the authors started gathering data with the intent of analyzing 
clients’ outcomes for publication. In my study, I present the first efficacy and safety 
analyses based on a large, retrospective data set where the women underwent MA outside 
of a research setting. Such analyses of large patient data sets could uncover efficacy 
differences between these protocols administered in a research setting versus in day-to-
day clinical practice. Another relevant gap in the literature exists around studies of 6- to 
8- hour dosing interval and simultaneous dosing in the United Kingdom. Guest et al. 
(2007) represent the only published study that explored the protocol using the 6-8-hour 
dosing interval in the UNITED KINGDOM, while Lohr et al. (2007) is the only 
published UK based study that explored the simultaneous dosing protocol. Both these 
studies have relatively small sample sizes, with Guest et al. having 215 women on the 6- 
to 8- hour dosing interval and Lohr et al. having 120 women in total. United Kingdom 
differs from many countries with liberal abortion legislature in that home administration 
of any abortifacient is not allowed under criminal law (Francome, 2017). Analyzing the 
safety of the efficacy of both the 6- to 8- hour dosing interval and simultaneous dosing, 
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my study findings could offer information that is of great value to women and healthcare 
providers in the United Kingdom and should be studied further. 
Theoretical Foundation 
None of the published quantitative studies that explore MA (and quantitative 
studies of abortion in general) mention or use a clear theoretical foundation. Only 
qualitative studies of the emotional effects on and personal experiences of women who 
had abortions (Foster et al., 2015; Taylor, 1998) have used foundations rooted in 
philosophical theory. This is not to say that theoretical foundations have no role in 
quantitative studies of abortion. When designing research, theory provides a foundation 
to start from and helps determine the methods and direction for that research (McEachan 
et al., 2008). Rather aesthetically, Creswell (2013) equates theoretical foundations of a 
study to rainbows that bridges the independent and the dependent variables. In my study, 
I use theories to form its foundation in a manner that aligns with the Theory to Research 
or Theory Then Research strategy” (Reynolds, 1971), where a theory is made explicit 
through continuous, reiterative interactions between it and empirical inquiry. 
The framework of my quantitative study is formed by postpositivism and 
empiricism (Theory of Knowledge, 2015). Postpositivist philosophy is a traditional 
approach that holds true for quantitative research (Creswell, 2013). The linear, uni-
directional nature of the study aligns with positivism, which states that science should not 
deviate from the observable and the measurable, and that the goal of knowledge is to 
describe phenomena that we experience (Trochim, 2006). The relative complexity of 
postpositivism when compared to positivism (Tashakkori & Teddlie, 1998) is a better fit 
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for interpreting and generalizing my study findings. As the authors showed, 
postpositivism allows controlled values to exist beyond hard objectivity. However, 
postpositivism is not limited to the observable (Clark, 1998). It is grounded in the idea 
that reality exists but cannot be fully understood or explained due to the multiplicity of 
causes and effects and social meaning. According to postpositivism, objectivity is an 
ideal, but requires a critical community of interpreters (Fischer, 1998).  
Postpositivism sees the goal of science as getting it right in reality (Trochim, 
2006). It takes a realist perspective of science and demands science to have precision, 
logical reasoning, and attention to evidence (Theory of Knowledge, 2015). If I find that 
one or both shorter protocols have an efficacy and safety that are either comparable or 
within acceptable range (albeit being slightly lower than the conventional protocol), 
postpositivist approach would allow me to still recommend that protocol (or protocols) as 
acceptable alternatives for women who seek a faster and simpler MA given the benefits it 
would bring to women across nations. The postpositivist approach places empirical 
studies in a broader framework based on a contextual understanding of social inquiry 
(Fischer, 1998), and allow some subjectivity into interpreting objective results, allowing 
for reality in the process of interpreting the results (Tashakkori & Teddlie, 1998). The 
authors showed how postpositivism allows a valuable imperfection in research findings 
that allows researchers to take the realities of life at the point in time of interpreting their 
results.  
This is aligned with the two simpler and shorter MA protocols included in my 
study being able to possibly improve women’s MA experience by shortening the time 
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needed and removing the need for an overnight experience.  Postpositivism holds reality 
as a social construction, shifts the focus of research findings to the situational context, 
and plays a critical role in interpreting the findings of the analysis with contextual aspects 
being taken into account (Fisher, 1998). Abortion has conventionally been surrounded by 
clashing of morals, controversies, and subjective viewpoints. In studying abortion, as I do 
in my study, remaining objective and grounding the findings on solid facts is important. 
Findings of postpositivist, quantitative studies and non-positivist qualitative studies tend 
to differ (Taylor, 1998). Referring to studies done on the effects of having an abortion on 
women’s psyche, Taylor (1998) stated that postpositivist studies that deal with tangible, 
measurable outcomes show that the effects are negligible while non-positivist studies that 
deal with subjective, intangible outcomes show significant negative consequences. 
Grounding my study in a postpositivist theoretical framework allows me to follow an 
objective path and set aside my views of abortion and my opinion of MA. The 
postpositivist approach allows the study to remain objective, for observers with varying 
stances on abortion can set them aside and focus on the tangible, quantitative, 
observation-based findings.  
Empiricism stresses that observation and measurement form the core of scientific 
study, (Trochim, 2006). Baird and Kaufmann (2008) showed how the theory recognizes 
the role of empirical evidence, the knowledge received through observation and 
experimentation in the formation of ideas. In my study, I derived results and conclusions 
using a quantitative, scientific approach, and I measured the efficacy and the safety of the 
MA protocols by scientific analysis of observed patient data. The empirical approach of 
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this study is reductionist, reducing research ideas into a small, discrete set of variables 
that comprise hypotheses and research questions (Creswell, 2013). Empiricism can be 
aligned with this research by assessing the effectiveness of the outcomes of those 
receiving a new intervention compared with outcomes of the group who received the 
conventional regimen (Davies & Nutley, 1999). Olsen (2004) claimed empiricism is 
behind a mathematics-fetishism that promotes quantitative study and puts off qualitative 
research. While meant as a criticism, it shows that empiricism is a good fit for studies 
where objective, quantitative analyses of independent, dependent, and control variables 
with the aim of quantifying the efficacy and safety of different MA protocols. The 
hypotheses of this study focus on objective efficacy and safety outcomes of two MA 
protocols. A postpositivist and empiricist approach supports measuring the efficacy and 
the safety of MA protocols using objective, measurable, dependent and control variables. 
Summary, Conclusions, and Transition 
Evidence shows abortion as a practice that has endured over millennia 
(Dellapenna, 2006; Devereux, 1967; Gordon, 1976). However, unsafe abortion persists, 
and causes between 5% and 15% of the annual global maternal deaths (Kassebaum et al., 
2014; Filippi, et al., 2016). The safe abortion methods currently in use fall into surgical 
and medical categories (Gopal et al., 2017; Li et al., 2017; Morris et al., 2017). MA is fast 
becoming women’s preferred option as it allows safe, cheaper, abortions in de-
medicalized settings (Raymond et al., 2013; Simmonds et al., 2017; Zane et al., 2015). 
Protocols of MIFE and MISO are the norm for MA (Raymond, et al., 2013; Gatter, et al., 
2015). The dosing interval between the drugs in current protocols makes MA a lengthy 
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procedure that takes multiple days (Aiken et al., 2017; Gatter et al., 2015). Over the last 3 
decades, many aspects of MA have been studied. MISO has been identified as the best 
prostaglandin to accompany MIFE (Avrech et al., 1991; Swahn & Bygdeman, 1989;). 
The most efficacious routes of MISO administration, and the dosages of MIFE and MISO 
that provides the best balance between good efficacy and acceptable side-effects are 
known (Raymond et al., 2013). The feasibility of at-home MA (Constant et al., 2017; 
Purcell et al., 2017) and lighter follow-up of MA (Anger et al., 2017; Chen et al., 2016) 
are deemed possible. The next frontier in MA research is shortening the dosing intervals. 
Limited research has been done in this area, with only 13 studies with small sample sizes 
having been published. During the literature review, neither studies that compared more 
than two protocols, nor studies that included more than one short MA protocol were 
found. No retrospective analyses of large data sets of MA clients who had the procedure 
in a non research setting have been conducted. 
In my study, I compared the efficacy and the safety of three MA protocols with 
varying dosing intervals between MIFE and MISO. The first uses a 24- to 36- hour 
dosing interval, the second a 6- hour dosing interval, and the third has the two drugs 
being administered simultaneously. The shorter protocols showing acceptable levels of 
safety and efficacy could make MA a shorter, simpler procedure, increasing access for 
many women. Chapter 3 outlines the retrospective cohort design that was used to analyze 
a large secondary data set of patients who had a MA using one of the three protocols 
being. Efficacy of a protocol was measured by the percentage of women who had a MA 
using the said protocol that required either additional abortifacients or a vacuum 
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aspiration to complete the procedure. Safety of a protocol was measured by the 
percentage of women who had a MA using the said protocol that experienced a 
complication that required clinical care. In addition, Chapter 3 explains in detail the 
specifics for the research design and approach, justification for this approach, selection 
criteria for setting and sample, instrumentation, and data analysis. Most importantly, 
Chapter 3 offers the associations between the assessed MA protocols and the safety and 
efficacy of the MA performed using those protocols. 
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Chapter 3: Research Method 
Introduction 
The purpose of this study was to compare the efficacy and the safety of three 
different MA protocols with varying dosing intervals between MIFE and MISO. The first 
protocol uses the conventional 24- to 36-hour dosing interval between the drugs and 
requires women to visit a health facility on two occasions on different days to complete 
it. The second protocol uses a 6-hour dosing interval between the drugs, with MIFE being 
taken in the morning and MISO during the afternoon of the same day. The third 
eliminates the dosing interval, with the two drugs being administered simultaneously. In 
this chapter, I will discuss the research design, methodology, and rationale for my study; 
the population under study; sample size; method and procedure for data collection; the 
instruments used for data collection; and how the data were analyzed. 
Research Design and Rationale 
Variables. 
I explored the relationships between a single independent variable and two 
dependent variables. There were two control variables (i.e., covariates) in the relationship 
for one of the dependent variables, and three control variables for the other. The variables 
were: 
Independent variable: I had a single independent variable, the MA protocol. This 
variable had three levels, the three protocols being different from each other 
according to the dosing interval length between the MIFE and the MISO. The first 
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protocol has a dosing interval of 24–36 hours, the second a dosing interval of 6–8 
hours, and the third uses simultaneous dosing.  
Dependent Variable 1: MA safety was the first dependent variable. A MA 
procedure received by a woman was deemed safe if the woman did not contact the 
clinic network within 1 week due to symptoms (i.e., either side effects or 
complications) that required her to be brought in for a follow-up consultation. 
This variable had two levels: safe and unsafe. 
Dependent Variable 2: MA efficacy was the second dependent variable. A MA 
procedure received by a woman was deemed efficacious if she did not have to 
take additional abortifacient doses or undergo a vacuum aspiration after the MISO 
dose. This variable had two levels: effective and ineffective. 
Control Variable (Covariate) 1: Gestational age, the advancement of the 
pregnancy at the time of the MA given in days, was a control variable when 
conducting analyses for both dependent variables (i.e., safety and efficacy). 
Control Variable (Covariate) 2: Number of past pregnancies, the total past 
pregnancies carried to term by the woman prior to the pregnancy for which she is 
seeking a MA, was used as a control variable only when analyzing the efficacy of 
the dependent variable. 
Control Variable (Covariate) 3: Maternal age, the age of the mother given in 






My chosen approach for this study was quantitative. The rationale behind my 
choice lies in the fact that a quantitative methodology aligned perfectly with the purpose 
of the study as well as the two research questions. Quantitative research is a means for 
testing objective theories by examining the relationship among variables (Creswell, 
2013). Choosing a retrospective cohort design followed the views of Creswell (2013) on 
quantitative designs in having assumptions, deductively testing theories, building in 
protections against bias, controlling for alternative explanations, and paying attention to 
being able to generalize and replicate study findings. Retrospective cohorts are 
observational designs and sometimes referred to as historic cohorts (Sedgwick, 2014). 
They are usually constructed from databases of healthcare records that have already been 
collected and the exposure to risk factors or to independent variables is usually recorded 
prior to the recording of the outcomes (Sedgwick, 2014). 
In this study, I compared the efficacy and the safety of three different MA 
protocols with varying dosing intervals between MIFE and MISO. The key difference 
among the protocols lay in the dosing interval between the MIFE and the MISO tablet 
administration. Cohort designs are suitable when describing subgroups within a 
population with respect to an outcome and a set of risk factors (Levin, 2006). Choosing a 
retrospective analysis of a secondary data set allowed me to capture a large sample size 
for each of the three protocols without a large time and resource cost. The large sample 
coming from a large clinic network spread widely across the United Kingdom where 
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demographics of women seeking abortion remains uniform (see Francome, 2017) 
minimizes selection bias (see Sedgwick, 2014). 
I used a retrospective cohort analysis and regression analyses to explore the 
relationships of the three protocols to the efficacy and safety of the protocols. In 
exploring the relationship between protocols and the safety of the procedures, I controlled 
for factors that impact the safety of MAs conducted using MIFE and MISO (i.e., 
gestational age and maternal age). In exploring the relationship between protocols and the 
efficacy of the procedures, I controlled for factors that impact the efficacy of MAs that 
use MIFE and MISO (i.e., gestational age, maternal age, and the number of past 
deliveries). 
The data that I extracted from an anonymized patient database captured over 100 
data points for each woman negates the risk of recall bias, which is a concern in 
retrospective cohort designs (see Sedgwick, 2014). Despite the database that captured 
patient data used in my study not having been initially constructed with the intention of 
identifying a cohort for future studies that explore relationships between the different MA 
protocols offered and the abortion outcomes, its use allowed me to conduct this 
retrospective study in a relatively cheap, quick, and easy manner. Creswell (2013) and 
Sedgwick (2014) stated these benefits of using pre collected, standardized, electronic 
records. The authors highlighted that retrospective cohort studies that use pre collected 
health data could miss the identification of some pertinent risk factors and not record 
them; however, the clinic network who produced my data set has a medical information 
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system that captures all patient characteristics that are known to affect the safety and the 
efficacy of MA procedures, which negated the said risk.  
This comprehensive capture of patient data allowed me to use the independent, 
dependent, and control variables that I have previously outlined in this study. The 
comprehensive nature of the Medical Information System and the fact that each clinic 
staffer who enters patient data to the system are well trained in entering patient 
information with little interpersonal variations negated the risk for inconsistent data sets 
that is a risk carried by retrospective cohort designs (see Sedgwick, 2014). With all MA 
protocols, both the expulsion of the products of conception as well as complications 
captured under my dependent variable of safety, occur within 3–4 days of administering 
MIFE and MISO (see Cleland et al., 2013; WHO, 2015). Furthermore, the data set from 
which I extracted data spans multiple years, with each woman being allocated a unique 
identifier that would capture her if she were to contact any of the clinics in the network 
from which the data set is drawn. Together, these factors mitigate the risk that Sedgwick 
(2014) pointed out regarding retrospective cohort designs potentially not spanning a 
length of time sufficient to capture clinical outcomes of interest. 
Methodology 
Population 
The population of a study refers to the complete set of relevant units of analysis, 
while the population sample of that study refers to a population subset that is used to 
generalize the study results back to the population (Frankfort-Nachmias & Nachmias, 
2008). The target population for my study was all women who sought a MA for 
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pregnancies below 9 weeks of gestation at a facility where the counselling and 
prescription is provided by trained clinical staff.  The population sample used in my study 
were women who sought a MA prior to the ninth week of gestational age at one of the 
largest abortion service networks in the United Kingdom. Estimating the size of my full 
population presented challenges. Of the 213 million pregnancies in world in 2012, over 
40 million were aborted (Sedgh et al., 2014; Vrachnis et al., 2016), with over half being 
carried out in a safe manner. Sedgh et al. (2016) estimated that approximately 60% of 
safe abortions in the world use MAs and that most of those are conducted in the first 
trimester. These statistics put the estimated size of my study population around 12 million 
women globally (per year). There were 190,406 abortions carried out in England and 
Wales in 2016, with MA being the method used in 62% of the total, or approximately 
120,000 (Department of Health, 2017). All MAs in the United Kingdom are carried out in 
the first trimester (Department of Health, 2017; Lancome, 2017). The medical 
organization from whose clinics I obtained my data set provides approximately 65,000 
safe abortion services in the United Kingdom annually. Over the last 3 years, the 
percentage of these procedures provided using MA has approximately been 50%. This 
percentage implies that my sample frame would comprise of approximately 25,000 
women who received a MA using one of the three MA protocols included in my study. 
Sampling 
I included all women who received a MA from the organization whose data were 
available in the 2017 data set except women whose anonymized records lacked data 
points that were critically related to the variables of the study in the analyses. I will 
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provide the sample size calculation in the next subsection. The information of all women 
who received a MA was in a single database and a specific data field allowed the 
identification of the MA protocol that a given woman opted for. Based on this data point, 
I separated women who had MAs using the three protocols into three distinct lists with 
serial numbers. The database records the discharge information of the women and 
allowed for the identification of women who did not complete the two drug protocols, 
who vomited or in other ways expelled the tablets. Only women who took both drugs in 
line with their chosen MA protocol and were discharged with the health providers’ 
contact information were included in the analyses. The presence of a data point that 
allowed for the identification of the MA protocol that each woman received made the 
process of dividing the main sampling frame into three groups by the protocol relatively 
simple. I assumed that the demographic characteristics of women who sought a MA at 
any clinics of the healthcare provider from whom my data set was obtained are similar. 
The data set allowed for this assumption to be tested by tabulating key demographics 
such as age, parity, and past abortions by clinic. Hence, no stratification was needed or 
carried out based on the individual clinic where a given woman who qualified to be 
included in the analyses received her MA. 
Power Analysis and Sample Size Determination 
I had one nominal independent variable (MA protocol) with three levels (Protocol 
A, B, C). The protocols differed from each other by the dosing interval between MIFE 
and MISO, with protocol A having a 24- to 36- hour interval, B having a 6- to 8- hour 
interval, and C having a 0-hour interval (simultaneous dosing). I had two dependent 
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variables (both binary). The first was MA protocol efficacy (efficacious/not) and the 
second was be MA protocol safety (safe/unsafe). There were three control variables in the 
efficacy analysis: Gestational age given in days, past pregnancies given as 1, 2, 3, etc., 
and maternal age given in years. Based on past evidence, only gestational age and 
maternal age was controlled for in the safety analysis. I used binomial logistic regression 
for the analyses, running six separate models, one for each MA protocol and binary 
dependent variable with the applicable covariates.  
Bivariate analyses were conducted prior to using the regression models. The first 
step was running separate bivariate analyses to study the relationships between my 
independent variable (MA protocol) and each dependent variable. This was followed by 
separate bivariate analyses between each of the two, dependent variable and each of the 
three control variables.  
Given the large size of the data set, which makes normality highly likely, the 
bivariate analyses would be done using a relatively simple test such as the chi-square. 
Two sets of chi-square test would be conducted. Assuming the three MA protocols were 
labelled a, b, and c, the first set of chi-square tests was done to compare the safety of 
protocol a to the safety of b, the safety of a to the safety of c, and the safety of b to the 
safety of c. The second set of chi-square tests compared the efficacy of protocol a to the 
efficacy of b, the efficacy of a to the efficacy of c, and the efficacy of b to the efficacy of 
c. The second set of chi-square tests was done between the dependent variables and each 
of the control variables. 
1. Chi-square gestational age with safety (all protocols combined) 
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2. Chi-square mothers’ age with safety (all protocols combined) 
3. Chi-square past pregnancies with safety (all protocols combined) 
4. Chi-square gestational age with efficacy (all protocols combined) 
5. Chi-square mothers’ age with efficacy (all protocols combined) 
6. Chi-square past pregnancies with efficacy (all protocols combined) 
The results of these bivariate analyses helped determine the empirical relationship 
between the MA protocols and their safety and efficacy. They also allowed me to identify 
the control variables that would be meaningful to include. These in turn, informed my 
regression modelling. My independent variable, the two dependent variables, as well as 
one control variable (past pregnancies) are categorical variables that can be directly used 
in the bivariate analyses. The other two control variables (maternal age and gestational 
age), which are continuous, required conversion to categorical variables (using age 
groups and gestational age given in weeks) for the bivariate analyses. 
Effect Sizes and Alpha Levels 
Effect size allows us to move beyond the simplistic question; does it work or not? 
to the far more sophisticated question; how well does it work in a range of contexts? 
(Coe, 2002). I used an effect size of 5% when conducting analyses on the efficacy of the 
different MA protocols. When conducting analyses on the safety of the different MA 
protocols, a much smaller effect size of 1% was used. These effect size choices are 
justified as follows. Effect sizes calculated from a very large sample it is likely to be 
more accurate than one calculated from a small sample (Coe, 2002), allowing me to draw 
confidence from the large data set I was using. Currently, below the MIFE and MISO 
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combination, the next most commonly used MA protocol category is the use of MISO as 
a stand-alone drug. The (WHO, 2015), the International Federation of Obstetrics and 
Gynecology (Morris, et al., 2017), and other institutions have included MISO only MA 
protocols for terminating pregnancies, up to 24 weeks. The efficacy of MISO only 
protocols in pregnancies with gestational ages below 10 weeks (as are the pregnancies 
included in my study) are in the 85% to 90% range (WHO, 2012, 2015). A robust 
systematic review of efficacy and safety of MA where the expulsion occurred at home 
across multiple countries, Ngo et al. (2011) demonstrated failure rates between 3% and 
14%. Compared to the approximately 95% efficacy of the conventional MIFE and MISO 
protocol (WHO, 2012, 2015), the MISO only protocols fall well behind. If the efficacy of 
either the MIFE and MISO protocol with a 6- to 8- hour dosing interval or the 
simultaneous dosing protocol (or both) is above 90%, they would be practical alternatives 
to the existing MA protocols. An effect size of 5% would enable me to detect if the 
efficacy of either protocol (6- to 8- hour dosing interval or simultaneous dosing) falls 
below 90%.  
The 1% effect size for safety is due to the very low complication rates seen with 
early MA. I could not find a single study that demonstrated a MA protocol that used a 
MIFE and MISO combination that had an adverse event rate of over 1%. Cleland et al. 
(2013) stated that protocols used for early MA have a low probability of clinically 
significant adverse events. In a large study of MA adverse effects that involved 233,805 
MAs provided in 2009 and 2010, the authors only recorded significant adverse events or 
outcomes in 1,530 women (0.65%). I assumed that 1% of women who opt for the 
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conventional (24- to 36- hour) protocol would face a significant safety event, while 
women who opt for one of the two shorter protocols would have a 2% likelihood of 
facing such a safety event.   
In both the efficacy and the safety analysis, I set an alpha of 0.05. I consider being 
able to identify significant difference in the efficacy or the safety among the three MA 
protocols with a 95% confidence level to be adequate. The study power was set at 80%, 
allowing an 80% probability of detecting a 5% difference in the efficacy and a 30% 
difference in the safety among the three protocols. G*Power software version 3.1.9.2 
(http://www.gpower.hhu.de/en.html) was used in all power and sample size estimations. 
The steps for the dependent variable efficacy (alpha 0.05, effect size 5%) for each MA 
protocol with the three covariates are as follows: 
1. Select ‘Z Tests’ and ‘Logistic Regression’ 
2. Select two tails.  
3. Click ‘Options’ tab  
4. select ‘Two Probabilities’  
5. The probability of an efficacious procedure with the conventional MA 
protocol is 0.95. For either of the shorter protocols, it is 0.90 
6. Alpha is 0.05. Power is 80%.  
7. All covariates, maternal age, past pregnancies, and gestational age (within the 
4 to 10-week range) have a low association with both efficacy and safety. 
Hence R2 for these would be set at 0.04. 
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8. X- distribution is set for binomial, X-papram π would be set at 0.5 as the 
number of women in the sample who opted for a given protocol from among 
the three is expected to be roughly equal. 
The steps for the dependent variable safety (alpha 0.05, effect size 30%) for each 
MA protocol with the two covariates are as follows: 
1. Select ‘Z Tests’ and ‘Logistic Regression’ 
2. Select two tails.  
3. Click ‘Options’ tab  
4. select ‘Two Probabilities’  
5. For safety, the probability of an efficacious procedure with the conventional 
MA protocol is 0.01. For the shorter protocols, it is 0.02 
6. Alpha is 0.05. Power is 80%.  
7. Both covariates, past pregnancies and gestational age (within the 4 to 10-week 
range) have a low association with both efficacy and safety. Hence R2 for 
these would be set at 0.04. 
8. X- distribution is set for binomial, X-papram π would be set at 0.5 as the 
number of women in the sample who opted for a given protocol from among 
the three is expected to be roughly equal. 
With the above approach, the sample size for efficacy for a given medical 
protocol is 917 and the sample size for safety for a given MA protocol is 4,883. The data 
set I used allows for sample sizes that easily exceeds the required sample sizes calculated 
above. Following each of the two analyses for the two dependent variables safety and 
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efficacy, a post hoc power analysis was carried out using G*Power. Post hoc power 
analyses done using the sample size and the effect size provided insights into the 
statistical validity of the results (specifically the likelihood of a Type-2 error). 
Data Acquisition 
All analyses in this dissertation are based on secondary data from women who 
opted for a MA from the reproductive health clinic network managed by the largest 
abortion providing agency in the United Kingdom. Experimental and quasi-experimental 
designs that could answer my research questions were decided against as such designs 
require much more intensive logistical, financial, and time resources (Creswell, 2013). 
With the less than 5% failure rate of early MA (WHO, 2015), capturing significant failure 
numbers in each protocol groups would require lengthy prospective follow up (Creswell, 
2013). Full experimental designs were also rejected as randomizing women into one of 
the MA protocols would interfere with their choice and raise ethical questions. This 
cohort design based on secondary analyses is appropriate for describing relationships 
between variables (Frankfort-Nachmias & Nachmias, 2008). The secondary analysis-
based design also has lower financial and temporal cost, allows the inclusion of multiple 
control variables, and removes risks of loss to follow-up (Levin, 2006; Sedgwick, 2014). 
Following discussion with the Walden University Institution Review Board 
(IRB), a formal request was made to the abortion provider organization for an 
anonymized data set of all women who obtained MAs from their clinics within the United 
Kingdom (Appendix A). permission was obtained from the Caldicott Guardian of the 
organization on the 17th of May 2018. The proposal was approved by the IRB (Approval: 
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04-26-18-0389171). Additionally, I successfully completed the National Institute of 
Health Human Research Protection training. No data of women who opted for surgical 
abortions (either using manual vacuum aspiration or using dilatation and curettage) was 
requested. Anonymization was done by those who maintain the health information 
systems of the organization, and the data set was given to me only after removal of all 
surgical abortion clients and the full anonymization of all MA clients.  
The data set included all non-identifier data points of all women who obtained a 
MA using one of the three protocols in question within 2017. The anonymization is in 
accordance with the Health Insurance Portability and Accountability Act of 1996. All 
women were identified by the unique personal identifier numbers generated by the health 
information system at the time of their initial registration. This number was used to 
follow each woman up through to the completion of their procedures and allowed a 
subsequent complaint or a visit to any of the organization’s clinics to be linked to the 
same person. The data set given to me did not contain any data that would provide clues 
to the individuals linked to a given personal identifier number.  
The health information system used by the medical organization is one developed 
specifically for the customized collection of their patient data. The data set was converted 
to an Excel database format following anonymization and delivered to me for the purpose 
of this study in said format. Information of each MA patient after anonymization included 
approximately 100 data points, giving the full Excel database approximately 3 million 
data points. Both to make the handling of the data set easier and to maximize the security 
of the patients’ data (despite anonymization), the data points that are irrelevant to the 
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analyses were removed. The number of data points of a given woman that would be 
required for the analyses included the MA protocol chosen, the times of the 
administration of both MIFE and MISO (together indicating the protocol chosen), the 
route used for the administration of MISO, the actual protocol, the woman’s age, 
gestational age at the time of the abortion, number of past pregnancies, and several data 
points that capture subsequent contacts, clinic visits, complaints, and follow up 
communications. A copy of the original anonymized data set was saved in a secure 
external hard drive with no online accessibility, while the simplified data set was used for 
all analyses from the point of its creation. 
Medical as well as surgical options are offered to every woman who contacts the 
medical organization seeking abortion options in the first 10 weeks of gestation. Those 
who choose MA are offered all three protocols being compared in my study, with the 
protocol a given woman opts for being her independent choice following a counselling 
session during which the three protocols are explained to them. The efficacy rates 
presented for each protocol are the rates based on the smaller studies that were outlined in 
Chapter 2. All women are provided with the same follow up options and have access to 
the same complication management options. There are no grounds to suspect significant 
differences of the key variables among women who opt for the three different MA 
protocols. 
Operationalization 
The independent variable (MA protocol) is defined based on the time gap between 
the oral 200 mg MIFE tablet and the vaginally inserted four 200 μg MISO tablets. The 
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three protocols are labelled 1, 2, and 3. Protocol 1 is the conventional protocol, where the 
time gap between MIFE and MISO was 24- to 36- hours. The time gap of Protocol 2 is 6- 
to 8- hours. In Protocol 3, the time gap is zero (MIFE and MISO administered 
simultaneously). The data set indicates the protocol that each woman received following 
counselling. This was used to separate women into the three protocol groups. The data set 
also records the exact time of the administration of MIFE and MISO for each woman. 
These were used to cross-check the accuracy of including a given woman in the protocol 
group she was allocated to. Women who opted for Protocols 1 or 2, who did not proceed 
(did not return to the clinic for the MISO) with the MISO despite receiving MIFE were 
excluded from the sample. This possibility did not arise in Protocol 3 due to the 
simultaneous administration of the two drugs. Women in Protocol Groups 1 and 2 who 
vomited the MIFE tablet were given a second. But for the purpose of the study, these 
were excluded as the time gap between the second MIFE and the MISO did not always 
correspond to the time gap of the particular protocol. 
The dependent variable MA efficacy was defined for a given woman based on 
whether she required either an additional dose of MISO or a vacuum aspiration to 
complete her uterine evacuation. This information for a given woman was available in the 
data set. The used MA protocol was considered to have been effective in women who did 
not require additional MISO dosing or vacuum aspiration for completing expulsion, with 
the protocol being deemed ineffective if either is required. The dependent variable MA 
safety was defined for a given woman based on whether she encounters symptoms (either 
side effects or complications) that require her to receive a follow up consultation at a 
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health facility within a week of her procedure (from the day/time when she received her 
MIFE dose). Due the unique patient identifier given to each woman who received care in 
the clinic network, any follow up medication, procedures, or referrals to other facilities 
for the management of conditions that cannot be managed in that particular clinic 
network she receives can be tracked. This allows the identification of women whose MA 
was non efficacious or ‘non safe’. In terms of the variable efficacy, an efficacious MA 
was coded 1 and a non efficacious MA coded 2. Similarly, a safe MA was coded 1 and an 
unsafe MA coded 2. 
The first control variable (Covariate 1) is gestational age. It is defined as the 
number of days the pregnancy has been in situ. For the initial bivariate analysis, 
gestational age was converted into a categorical variable by grouping women into ranges 
of days (e.g. gestational age days 36- to 42 coded as 1, 43- to 49 coded as 2, 50- to 56 
coded as 3). These groups ranged from 36 days to 69 days, with each group being 7 days 
in length. In the main (logistic regression) analyses, gestational age was recoded as an 
ordinal variable with the advancement of the pregnancy given in weeks. The second 
control variable (Covariate 2) is the number of past pregnancies, defined as the total 
pregnancies carried to term by the woman prior to the pregnancy for which she is seeking 
a MA. This was coded in line with the number of past pregnancies, as 1, 2, 3, up to 9 and 
a last group for 10 or more. Being a ratio variable, past pregnancies did not require any 
changes for either the bivariate analysis or the regression analyses. The third control 
variable (Covariate 3) is maternal age, the age of the woman in years at the time of her 
seeking the MA. Similar to gestational age, this was converted to a categorical variable 
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for the bivariate analysis by grouping women in to age ranges. Each age group had a 5-
year range. Those <15 years were coded as 1, the group 15- to 19 were coded 1, 20- to 24 
coded 2, up to the group 35- to 39, which was coded 6. Those aged 40 or above were 
coded as 7. For the regression analyses, maternal age was used as an ordinal variable with 
the age of each woman given in years. 
Data Analysis Plan 
Once the data set is handed to me by the medical organization following 
organization approval and the full data set anonymization, the first step was the division 
of all women who received a MA in to three groups based on the MA protocol that they 
opted for and received. In each of the three groups, women whose records miss the data 
points critical for the analyses were excluded, with a clear record of all excluded women 
from each protocol group being maintained. The number of women in each of the three 
groups whose data records are complete with regards to all data points required for the 
analyses were compared against the sample size estimations conducted to ensure that 
each protocol group has adequate members for the study purpose. All analyses were 
conducted using Statistical Package for the Social Science (SPSS) version 25 (released 
June 2017), which allows stronger regression analyses, as well as more options for 
presenting data and results using graphs and charts. 
Binomial logistic regression was used to answer the two research questions. The 
choice of binomial logistic regression is based on the fact that both my two dependent 
variables are binary (safe vs. unsafe, and efficacious vs, inefficacious).With the first 
question, I explored the relationship between the MA protocol (6- to 8- hours and 
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simultaneous vs. 24- to 36- hours) and the safety of the procedure measured by the 
percentage of women who experienced a complication that required facility care after 
controlling for factors that impact the safety of MAs conducted using MIFE and MISO 
(gestational age and the age of the pregnant woman). The null hypotheses was that there 
is no statistically significant relationship between the MA protocol time gap (6- to 8- 
hours and simultaneous vs. 24- to 36- hours) and the safety of the procedure as measured 
by the percentage of women who experienced a complication that required facility care 
after controlling for factors that impact the safety of MAs conducted using MIFE and 
MISO (gestational age and the age of the pregnant woman). The alternate hypothesis is 
that there is a statistically significant relationship between the MA protocol (6- to 8- 
hours and simultaneous vs. 24- to 36- hours) and the safety of the procedure as measured 
by the percentage of women who experienced a complication that required facility care 
after controlling for factors that impact the safety of MAs conducted using MIFE and 
MISO (gestational age and the number of past deliveries). 
With the second research question, I explored the relationship between the MA 
protocol (6- to 8- hours and simultaneous vs. 24- to 36- hours) and the efficacy of the 
procedure as measured by the percentage of women who required a second intervention 
to complete the expulsion after controlling for factors that impact the effectiveness of 
MIFE and MISO (gestational age, maternal age, and the number of past deliveries). The 
null hypothesis is that there is no statistically significant relationship between the MA 
protocol time gap (6- to 8- hours and simultaneous vs. 24- to 36- hours) and the efficacy 
of the procedure was measured by the percentage of women who required a second 
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intervention to complete the expulsion after controlling for factors that impact the 
effectiveness of MIFE and MISO (gestational age, maternal age, and the number of past 
deliveries). The alternative hypotheses was that there is a statistically significant 
difference between the MA protocol (6- to 8- hours and simultaneous vs. 24- to 36- 
hours) and the efficacy of the procedure as measured by the percentage of women who 
required a second intervention to complete the expulsion after controlling for factors that 
impact the effectiveness of MIFE and MISO (gestational age, maternal age, and the 
number of past deliveries). In answering the first question, the relationship between the 
MA protocol (Protocol 1, 2, or 3) and the safety of the resulting MA was examined while 
controlling for gestational age (given in weeks) and maternal age (given in years). In 
answering the second question, the relationship between the MA protocol (Protocol 1, 2, 
or 3) and the efficacy of the resulting MA was examined while controlling for gestational 
age (given in days), maternal age (given in years), and past pregnancies given as 1, 2, 3, 
and 4 or more. 
Data Interpretation 
In line with the problem statement and the purpose of the study, I explored the 
relationships between the MA protocols and each protocol’s efficacy and safety through 
my two research questions. From a practical perspective, the key practical consideration 
was whether the efficacy and the safety of the two shorter protocols are at levels that 
would make either or both of them suitable to be offered as an alternative to the 
conventional, lengthy protocol.  If the efficacy or the safety of a shorter protocol exceeds 
that of the conventional (24- to 36- hour) protocol, that would be considered a positive 
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result. If the efficacy of a shorter protocol was lower than that of the conventional 
protocol, but if the efficacy difference is less than 5%, I considered the shorter protocol to 
be a likely alternative to the conventional protocol from an efficacy perspective. If the 
safety of a shorter protocol is lower than that of the conventional protocol, but the 
significant adverse event rate of the two protocols differ by less than 1% (e.g. 1% for the 
conventional protocol and <2% for the shorter protocol), I considered the shorter protocol 
to be a likely alternative to the conventional protocol from a safety perspective. 
Threats to Validity 
Multiple factors threaten the reliability and the validity of a study. Creswell 
(2013) showed subject selection, history, maturation, experimenter bias, mortality, 
compensatory demoralization, diffusion, regression towards the mean, and confounding 
as common threats to internal validity. Most of these do not threaten the internal validity 
of my study due to its design. From the threats named in Creswell, history, mortality, and 
maturation are not of concern due to the retrospective design and the rigorous data 
cleaning undertaken. Due to the retrospective nature, experimenter bias and Ambiguous 
temporal precedence also do not apply. With no instruments used, and having no Pre–
Post test design, participant sensitization is also not a concern.  
Compensatory demoralization is not a concern as the study is retrospective, and 
each woman received the MA protocol that she selected, rather than being allocated to a 
given protocol for study purposes. The selection of participants and confounding could 
hold potential threats to validity in my study, as the rationale behind a given woman’s 
choice of MA protocol cannot be determined with certainty. There may be unforeseen 
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confounding variables that affect women’s choice of a given protocol, although this 
likelihood is extremely unlikely. The likelihood of these threatening the internal validity 
is further lessened due to the data set including women who came for procedures in 
different parts of the United Kingdom (Zwarenstein, et al., 2008). Demographic analyses 
of the women who chose each of the three protocols were carried out to detect possible 
trends that suggest significant variations in variables that could affect the safety and the 
efficacy of a MA among women who chose each protocol. 
The findings of my study could potentially lead to changes in MA protocols in 
many countries. Hence the generalizability of the results (external validity) is a major 
concern and demonstrating the generalizability of the study findings is of key importance. 
Metcalfe and Lynch (2002) differentiated between generalizability across situations and 
generalizability across peoples. Creswell (2013) and Trochim and Donnelly (2001) 
outlined the common factors that threaten the external validity of studies. Of these, pre 
and post test effects as well as reactivity, Hawthorne effect, and Rosenthal effect do not 
threaten my study due the retrospective nature of the design that I used. However, 
Aptitude-treatment Interaction (interaction effects of selection and experimental 
variables) was a potential concern, especially when considering the generalization of my 
results to settings outside of the United Kingdom. This arises due to the study sample 
being drawn from a group of women who were mostly British that visited the clinics of a 
specific abortion providing agency.  
Based on demographic information on abortion seeking women in the United 
Kingdom and the United States (Francome, 2017), it can safely be assumed that this 
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concern is negligible for those countries. Negating concerns around interaction effects of 
selection and experimental variables for women in countries that vastly differs from the 
United Kingdom however is more challenging. Similarly, the reactive effects of 
experimental arrangements (situation under which MA is performed) could also a 
potential threat to external validity. In the study sample, in line with the United Kingdom 
law, all women have received both MIFE and MISO with close medical supervision and 
high-quality counselling. The safety and efficacy levels seen in such a setting are likely to 
exceed those seen with the same protocol but with the two abortifacients being 
administered under poor or absent supervision, and where the quality of the counselling 
received by women is questionable. In my opinion, this is the biggest threat when 
attempting to generalize the study findings to settings outside of the United Kingdom. 
Considering the above arguments related to the internal and the external validity 
of my study, I have confidence in its ecological validity (Brewer & Crano, 2000; 
Schmuckler, 2001). According to these authors, ecological validity of my study refers to 
whether I can generalize my study observations to natural behavior in the world. If the 
safety and the efficacy of either of the shorted MA protocols (simultaneous dosing or the 
6- to 8- hour dosing interval) are found to be within acceptable range of the safety and the 
efficacy of the conventional (24- to 36- hour dosing interval) protocol, the likelihood of 
that shorter protocol being used as an alternative to the conventional protocol in the 
United Kingdom would be very high. Considering the anatomical and physiological 
similarities of the female reproductive systems of women across our species, logic would 
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dictate that such findings would also make that shorter protocol a suitable alternative to 
the conventional protocol in other countries as well. 
Ethical Procedures 
The ethical requirements for the suggested study are expected to be relatively 
light considering what is proposed is the retrospective analyses of a secondary data set 
(Research Ethics Guidebook, n.d.). However, I have had my fair share of ethical pitfalls 
to avoid and ethical permissions to be obtained. Kaplan (2014) stated that electronic 
health records and secondary use of such, while enabling exciting opportunities for 
improving health and health care, exacerbate privacy concerns. The author specified such 
concerns around secondary health data, showing how intimacies are revealed in the 
interest of good health care and how clinicians’ professional and fiduciary duties include 
a duty of confidentiality.  
Discussions were had with both the IRB and the United Kingdom’s relevant 
bodies regarding the requirements for ethical clearance. Guidance was sought regarding 
the United Kingdom ethical approvals needed from the Confidentiality Advisory Groups 
of the Health Research Authority (National Health Service, 2017). In line with their 
guidance, the second step was to discuss the study and the anonymization process with 
the Caldicot Guardian of the healthcare organization that provided the MAs included in 
the study and whose data set I used for this study. Once written approval is obtained by 
the Caldicot Guardian, that was submitted to IRB together with the full IRB application 
for obtaining ethical clearance to obtain the data set and proceed with the analyses.  
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Kaplan (2014) states that the European Union Data Protection Directive as well as 
almost every single privacy statute and regulation in the U.S. and Europe embraces the 
assumption that anonymization protects privacy and extends safe harbors to those who 
anonymize their data. Tripathy (2013), discussing ethical issues and challenges of 
secondary data analysis, also states that fully anonymized patient data is considered to 
protect individuals’ privacy, and outlines what full anonymization entails. The data set 
was anonymized by the data guardian(s) of the healthcare organization providing the 
data. All direct identifiers were removed, and the data extracted from the organizations 
health information system on to an Excel database. The unique patient identifier numbers 
allocated by the health information system were replaced by other numbers (coded) in a 
manner that the same unique code replaced a given unique patient identifier in each 
instance that the said identifier appears. However, due to the coding, it was impossible 
for me to use the data set to identify any patient even if I gain access to the health 
information system of the organization. Furthermore, I was required to provide 
assurances to the Caldicot Guardian of the healthcare organization that I would not share 
the data set with any entity outside of the European Economic Area, even for future 
publication purposes. 
Summary and Transition 
In this chapter I outlined the purpose of my study with a special focus on the 
research design of my study, the methodology I used, and the rationale behind my study. 
I also explored the population used in the study, the details of my sample size and power 
calculations, as well as the rationale behind the effect sizes I chose for my two research 
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questions. I outlined the method and procedure I used for data collection, steps taken to 
protect the women whose medical data were used in my analyses, and how the data were 
analyzed. Finally, I presented the threats to the internal and external validity of my study 
and what steps were taken to minimize or negate those threats. In the fourth chapter, the 
results of the analyses used to test the two research questions and hypotheses generated 
for this study are presented. 
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Chapter 4: Results  
Introduction 
In this chapter, I will describe the analyses conducted to address the research 
questions. In this quantitative study, I used regression analyses to explore the 
relationships of three MA protocols to the efficacy and safety of the procedures resulting 
from those protocols. In exploring these relationships, factors that have been shown to 
impact the safety and efficacy of MAs conducted using MIFE and MISO (i.e., gestational 
age, maternal age, and the number of past deliveries) were controlled for.  
The independent, dependent, and the control variables included in my study are 
outlined in Table 1. I had one independent variable (i.e., MA protocol, decided by the 
dosing interval) with three levels (i.e., dosing interval of 24- to 36-hours, dosing interval 
of 6- to 8-hours, and simultaneous dosing). There were two dependent variables: safety 
(decided based on whether a given client faced a complication that required healthcare or 
not) and efficacy (decided based on whether a given client required an intervention to 




Variable name  Type of variable Level of measurement 
Medical abortion protocol Independent variable Nominal 
Maternal age Control variable Ordinal  
Gestational age Control variable Ordinal 
Past pregnancies Control variable Ordinal 
Medical abortion efficacy Dependent variable Nominal; dichotomous 




Each dependent variable had two levels (i.e., efficacious or not and safe or 
unsafe). I controlled for all three control variables (i.e., gestational age, maternal age, and 
past pregnancies) when exploring the relationship between the MA protocol and 
procedural efficacy. Only gestational age and maternal age were controlled for when 
exploring the relationship between the MA protocol and procedural safety. The two 
research questions and the corresponding hypotheses were as follows: 
Research Question 1: What is the relationship between the MA protocol time gap 
(i.e., 6 hours vs. 24–36 hours vs. simultaneous) and the safety of the procedure as 
measured by the percentage of women who experienced a complication that 
required medical care after controlling for factors that impact the safety of MAs 
conducted using MIFE and MISO (i.e., gestational age and maternal age)? 
H01: There is no statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24–36 hours vs. simultaneous) and the 
safety of the procedure as measured by the percentage of women who 
experienced a complication that required medical care after controlling for 
factors that impact the safety of MAs conducted using MIFE and MISO 
(i.e., gestational age and maternal age). 
HA1: There is a statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24–36 hours vs. simultaneous) and the 
safety of the procedure as measured by the percentage of women who 
experienced a complication that required medical care after controlling for 
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factors that impact the safety of MAs conducted using MIFE and MISO 
(i.e., gestational age and maternal age). 
Research Question 2: What is the relationship between the MA protocol time gap 
(6 hours vs. 24–36 hours vs. simultaneous) and the efficacy of the procedure as 
measured by the percentage of women who required a second intervention to 
complete the expulsion after controlling for factors that impact the effectiveness 
of MIFE and MISO (i.e., gestational age, maternal age, and the number of past 
deliveries)? 
H02: There is no statistically significant relationship between the MA 
protocol time gap (i.e., 6 hours vs. 24–36 hours vs. simultaneous) and the 
efficacy of the procedure as measured by the percentage of women who 
required a second intervention to complete the expulsion after controlling 
for factors that impact the effectiveness of MIFE and MISO (i.e., 
gestational age, maternal age, and the number of past deliveries). 
HA2: There is a statistically significant difference between the MA 
protocol time gap (i.e., 6 hours vs. 24–36 hours vs. simultaneous) and the 
efficacy of the procedure as measured by the percentage of women who 
required a second intervention to complete the expulsion after controlling 
for factors that impact the effectiveness of MIFE and MISO (i.e., 
gestational age, maternal age, and the number of past deliveries). 
In this chapter, I will discuss the participant demographics and descriptive 
statistics, followed by details of the methods used to address each of the questions. This 
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will include the use of binomial logistic regression analyses to statistically analyze the 
safety and efficacy of the three MA protocols studied. The chapter will conclude with an 
overall summary of results.  
The data used to formulate the results were retrospective and came from the 
patient database of one of the United Kingdom’s largest providers of safe abortion care. 
The data captured all women who received MAs in the year 2017. The gestational age for 
MA was capped at 9 weeks. I obtained the data following receiving approvals from the 
medical provider organization as well as Walden IRB. The data were anonymized to meet 
the United Kingdom’s stringent patient data protection requirements, and the 
anonymization process aligned with the European Union medical data protection 
requirements. 
Data Collection 
The data for this study came from one of the United Kingdom’s largest safe 
abortion care providers. The data set captured all women who had a MA (capped at 10 
weeks’ gestation) between January 2017 and June 2018. Following approval from the 
Caldicott Guardian of the organization and receiving Walden’s IRB approval, I received 
a fully anonymized data set that included all women who had a MA within the 
aforementioned period from the organization. The original Excel extract from the health 
information system did not contain details of patients referred for facility care for 
complications and severe adverse events. Records of 878 referrals were obtained 
separately from the organization’s United Kingdom-wide call-center that provides 
information, makes patient bookings, and manages follow up and referrals. The center 
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maintains records of all referrals made for complications and adverse events. The two 
data sets were combined prior to anonymization using unique patient identifiers included 
in both data sets. All 878 referral records could be matched to corresponding clinical 
records. The data were transferred to me following anonymization. 
The combined data set contained records of 58,672 women who received a MA 
between January 2017 and June 2018. Records of women who sought surgical abortion 
had been removed. I then cleaned the combined data set, removing data fields that were 
not applicable to the analyses and patient records that were incomplete or contained 
invalid figures. Of the 58,672 records in the data set, 1,555 were removed because the 
MA protocol used could not be clearly determined. I removed a further 638 because they 
were duplicated (i.e., multiple database entries made for a single procedure). Another 424 
were removed because the gestational age was not entered (i.e., given as 0 weeks) and 63 
removed because the past pregnancy number was inaccurate (i.e., negative values 
shown). Finally, 24 were removed due to invalid gestation age figures (see Figure 2). 
The cleaned data set included records of 55,968 women who chose one of the 
three MA protocols. Each record included all required variables (i.e., protocol chosen, the 
patient’s age, the gestational age at presentation, past pregnancy number, the abortion 
outcome, and if the patient was referred for medical care due to complications and severe 
adverse events). There were no major discrepancies in data collection when compared to 
the data collection plan outlined in Chapter 3. I had not envisioned the need to extract 
data from two (i.e., clinical and call center) data sources earlier. This was not a major 
discrepancy because the final anonymized data set handed over to me was in line with 
82 
 
that outlined in Chapter 3. Another unexpected finding was that the number of patients 
who opted for the 6- to 8-hour protocol was much smaller than the numbers that opted for 
the conventional and the simultaneous protocols. 
 
 
Figure 2. Data cleaning process. 
424 removed due to missing 
gestational age  
638 removed due to 
duplication 
1,555 removed due to MA 







63 removed due to past 
pregnancies unclear 
55,968 Records 
Included in analyses 
24 removed due to inaccurate 




I imported the cleaned Excel data to SPSS for Windows (Version 25). The 
descriptive analysis for demographic data included the numbers of patients that chose 
each protocol and the percentages, means, and standard deviations for patient age, 
gestational age, and past pregnancies among patients who opted for each abortion 
protocol. Hypothesis testing was completed using binomial logistic regression. I 
conducted bivariate analyses prior to regression modelling. First, separate bivariate 
analyses were done to study the relationships between the independent variable (i.e., MA 
protocol) and each dependent variable. For this purpose, two sets of chi-square test were 
conducted. With the three MA protocols labelled 1, 2, and 3, the first set of chi-square 
tests compared the efficacy of the three protocols. The second set of chi-square tests 
compared the safety of the three protocols. I conducted another set of chi-square tests 
between the dependent variables and the control variables relevant to each dependent 
variable to help determine the empirical relationship between the MA protocols and their 
safety and efficacy as well as confirm the suitability of the control variables to be 
included in the regression analyses. 
To answer the first question, I examined the relationship between the MA 
protocol (i.e., Protocol 1, 2, or 3) and the safety of the resulting MA while controlling for 
gestational age (given in days) and past pregnancies (given as 1, 2, 3, and 4 or more). To 
answer the second question, I examined the relationship between the MA protocol (i.e., 
Protocol 1, 2, or 3) and the efficacy of the resulting MA while controlling for gestational 
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age (given in days), maternal age (given in years), and past pregnancies (given as 1 to 9 
and 10 or more). 
Statistical Power Analyses 
Post hoc power analyses were carried out using G*Power software Version 
3.1.9.2 (http://www.gpower.hhu.de/en.html). Post-hoc power analyses were done for 
binary logistic regression analyses. The safety and the efficacy of the conventional 
protocol was compared to the safety and efficacy of the 6- to 8- hour protocol and those 
of the simultaneous protocol. 
The efficacy of the conventional protocol was taken as 95% (H1 = 0.95). 
The efficacy of the other two protocols was taken as 90% (H0 = 0.90).  
The safety of the conventional protocol was taken as 99% (H1 = 0.99). 
 The safety of the other two protocols was taken as 98% (H0 = 0.98).  
The alpha was set at 0.05 for all analyses. 
For efficacy analyses, the odds ratio obtained when comparing the conventional 
protocol to the simultaneous protocol was 1.034. The odds ratio when comparing the 
conventional protocol and the 6- to 8- hour protocol, the odds ratio was 0.210. For the 
safety analyses, the odds ratio between the conventional protocol and the simultaneous 
protocol was 0.524. The odds ratio between the conventional protocol and the 6-8-hour 
protocol was 0.386. For both the efficacy and the safety analyses, the simultaneous 
protocol sample size was 27,616. For both the efficacy and the safety analyses, the 6- to 




The power values of the different analyses achieved according to the above are: 
Efficacy comparison conventional vs. simultaneous protocol = 71.8% 
Efficacy comparison conventional vs. 6- to 8- hour protocol = 100% 
Safety comparison conventional vs. simultaneous protocol = 100% 
Safety comparison conventional vs. 6- to 8- hour protocol = 100% 
Three of these power estimates exceed the required sample size estimations that were 
predicted in Chapter 3. Due to the small difference in efficacy (OR = 1.034) between the 
conventional and the simultaneous protocols, the sample size of 27,616 was insufficient 
(a sample size of 34,572 is required) for the power of 80% to be reached. 
Representativeness of The Sample to The Population of Interest 
The data set includes patient records from clinical across the United Kingdom. 
The abortion provider organization has 42 clinics across England, Scotland, and Wales. I 
consider the data to be representative of UK women of reproductive age. The data set 
captured all women who sought a MA in all 42 clinics between January 2017 and June 
2018. Only the records of 2,704 patients were removed from the data set. The removal 
was only based on the completeness of patient records and was not based on any patient 
characteristics. This removal of 4.6% of the original data set is insufficient to affect the 
representativeness of the data.  I would also consider the sample to be globally 
representative of women who seek abortion before 10 weeks. The conventional protocol 
is what is recommended by the WHO for global use. That recommendation is based on 
multiple studies that showed the protocol to be effective irrespective of patients’ 
nationality or other characteristics that might change based on patients’ nationality. This 
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suggests that for the purpose of MA prior to 10 weeks of gestation, women across the 
globe shows homogeneity with regards to abortion protocol effectiveness and safety. 
Intervention Fidelity 
No deviations from the protocols explained in Chapter 3 were detected in patient 
records. All three protocols were in line with what was outlined in the first three chapters. 
While occasional deviations in practice (not captured in the patient records) cannot be 
ruled out, intervention fidelity is safe to assume. Serious adverse events and severe 
complications are captured in the analyzed data set and they are included in the analyses 
on protocol safety 
Results 
Descriptive Statistics 
A total of 55,968 patients were included in the analyses. Of these patients, 24,483 
accepted the conventional protocol, 3,869 accepted the 6- to 8- hour protocol, and 27,616 
accepted the simultaneous protocol. Patients’ age breakdown was; <15-years [n = 32 
(0.06%)], 15-19-years [n = 5,803 (10.4%)], 20-24-years [n = 15,140 (27.1%)], 25-29-
years [n = 14,589 (26.1%)], 30-34-years [n = 10,739 (19.2%)], 35-39-years [n = 7,174 
(12.8%)], and ≥40-years [n = 2,491 (4.4%)]. The median age group was 25-29-years 
(Table 2). Gestational ages (Table 3) were; 4 weeks [n = 67 (0.12%)], 5 weeks [n = 7,194 
(12.9%)], 6 weeks [n = 22,332 (39.9%)], 7 weeks [n = 14,052 (25.1%)], 8 weeks [n = 
9,601 (17.2%)], and 9 weeks [n = 2,722 (4.9%)]. The mean of the gestational age was 6.6 
weeks (SD = 1.07). The number of past pregnancies (Table 4) were; 0 [n = 17,763 
(31.2%)], 1 [n = 10,685 (18.8%)], 2 [n = 9,215 (16.2%)], 3 [n = 7,632 (13.4%)], 4 [n = 
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4,890 (8.6%)], 5 [n = 2,771 (4.9%)], 6 [n = 1,492 (2.6%)], 7 [n = 737 (1.3%)], 8 [n = 339 
(0.6%)], 9 [n = 206 (0.4%)], and ≥10 [n = 238 (0.4%)]. The mean of the past pregnancies 
was 1.91 (SD = 1.99). 
 
Table 2 





(n = 55,968) 
Conventional 
Protocol 
(n = 24,483) 
6-8-Hour 
Protocol 
(n = 3,869) 
Simultaneous 
Protocol 
(n = 27,616) 
< 15 0.1% 0. 1% 0.1% 0.1% 
15-19  10.3% 9.0% 9.2% 11.8% 
20-24  27.1% 26.8% 29.3% 27.0% 
25-29 26.1% 26.7% 26.7% 25.4% 
30-34 19.2% 19.8% 18.3% 18.8% 
35-39 12.8% 13.2% 12.9% 12.4% 
≥ 40 4.5% 4.5% 3.6% 4.5% 
 
Table 3 








(n = 24,483) 
6-8-Hour 
Protocol 
(n = 3,869) 
Simultaneous 
Protocol 
(n = 27,616) 
4  0.1% 0.2% 0.1% 0.1% 
5 12.9% 16.2% 8.1% 10.6% 
6 39.9% 45.2% 35.7% 35.8% 
7 25.1% 23.8% 28.3% 25.8% 
8 17.2% 13.7% 21.0% 19.7% 











(n = 55,968) 
Conventional 
Protocol 
(n = 24,483) 
6-8-Hour 
Protocol 
(n = 3,869) 
Simultaneous 
Protocol 
(n = 27,616) 
0  31.2% 29.4% 32.1% 33.8% 
1 18.8% 18.8% 20.2% 19.2% 
2 16.2% 16.8% 17.7% 16.0% 
3 13.4% 14.5% 13.4% 12.9% 
4 8.6% 9.2% 8.0% 8.4% 
5 4.9% 5.4% 3.9% 4.7% 
6 2.6% 2.9% 2.5% 2.5% 
7 1.3% 1.5% 1.0% 1.2% 
8 0.6% 0.7% 0.6% 0.5% 
9 0.4% 0.4% 0.2% 0.3% 
≥10 0.4% 0.5% 0.4% 0.4% 
The bivariate analyses for comparing the two outcomes of the protocols are given 
below. They include the Pearson Chi-square value as well as the Cramér's V value for 
each of the two analyses. Table 5 outlines the bivariate analyses for efficacy while Table 
6 outlines the bivariate analyses for safety (no covariates included). 
Table 5 
Bivariate Analyses for The Efficacy of The Three Protocols 
Outcome  Protocol 1 Protocol 2 Protocol 3 
Failures  374 284 439 
Expected failures 479.9 75.8 541.3 
Total cases 24,483 3,869 27,616 
 
 Value p value 
Pearson Chi-Square 626.384 0.000 





Bivariate Analyses for the Safety of the Three Protocols 
Outcome  Protocol 1 Protocol 2 Protocol 3 
Complications  232 103 543 
Expected complications 384.1 60.7 433.2 
Total cases 24,483 3,869 27,616 
 
 Value p value 
Pearson Chi-Square 119.391 0.000 
Cramér's V 0.046 0.000 
With no control variables factored in, there are weak/very weak associations (both 
Cramér's V values are below 0.15) among the efficacy and the safety of the different MA 
protocols. These weak/very weak associations are statistically significant (both p values 
are below 0.0001). Tables 7 and 8 show the results of the chi-square tests conducted 
between the dependent variables and the control variables relevant to each dependent 
variable.  These two analyses help determine the suitability of the control variables to be 
included in the regression analyses that analyse the empirical relationships between the 
MA protocols and their safety and efficacy. 
Table 7 
Bivariate Analyses – Covariates for Efficacy 
Covariate  Pearson Chi-square df p value 
Maternal Age 57023.827 7 0.000 
Gestational Age 72.716 5 0.000 




The analysis justified the inclusion of all three covariates (maternal age, 
gestational age, and past pregnancies) in the regression modelling for the dependent 
variable efficacy. Accordingly, the regression analysis for efficacy was done with all 
three covariates included. Protocol 1 (conventional) was taken as the baseline. Table 9 
gives the regression analysis results for MA efficacy. 
Table 8 
Bivariate Analyses - Covariates for Safety 
Covariate  Pearson Chi-square df p value 
Maternal Age 56944.039 7 0.000 
Gestational Age 72.196 5 0.000 
Past Pregnancies 7.205 10 0.706 
The analyses justify the inclusion of two covariates (maternal age and gestational 
age) in the regression modelling for the dependent variable safety. The inclusion of past 
pregnancies is not justified. Accordingly, the regression analysis for safety included two 
covariates. Protocol 1 (conventional) was taken as the baseline in the safety analysis as 
well. Table 10 gives the regression analysis results for MA safety. 
Statistical Assumptions as Appropriate to the Study 
The dependent variables were binary, the sample sizes are large, and the coding is 
done in a way that (Y=1) in the probability of as event occurring (MA failure, and severe 
complication or adverse event). A stepwise approach used ensures that the models fit 
correctly. A factor analysis prior to running the logistic regression analyses showed no 
significant multicollinearity, which is also assured because the abortion protocols are 
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independent of each other. Linearity of independent variables and log odds is assured by 
the independent variable being categorical. 
Table 9 
Binomial Logistic Regression Output – Protocol Efficacy 
   95% CI For OR 
Variable OR Significance Lower Higher 
Protocol 1     
Protocol 2 0.210 0.000 0.178 0.246 
Protocol 3 1.034 0.647 0.897 1.191 
Maternal Age 0.822 0.000 0.782 0.864 
Past Pregnancies 0.977 0.175 0.945 1.010 
Gestational Age 0.811 0.000 0.767 0.858 
Regression results show a statistically significant difference (p < 0.0001) between 
the efficacy of the conventional protocol and the 6- to 8- hour protocol (Protocol 2). 
There is no such difference between the conventional (Protocol 1) and the simultaneous 
(Protocol 3) protocol. The odds-ratios suggest that the 6- to 8- hour protocol has a 79% 
higher likelihood of failure compared to the conventional protocol (OR = 0.210, 95% CI: 
0.178 - 0.246). The simultaneous protocol has a 3.4% lower efficacy (OR = 1.034, 95% 
CI: 0.897-1.191) but this is not significant (p = 0.647). The null hypothesis is rejected due 
to the statistically significant difference between the conventional and the 6-8-hour 
protocol (Protocol 2). 
The analysis shows that maternal age and gestational age affects the efficacy of 
MA protocols in a statistically significant manner (p < 0.0001). The number of past 
pregnancies does not. Each advance in maternal age along the 5-year age blocks used in 
the analysis increases the risk of MA failure by 17.8%. Each week’s advance in 
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gestational age increases the risk of MA failure by 18.9%. While each past pregnancy 
increases the risk of MA failure by 2.3%, this effect is not statistically significant. This 
differs from the result of the bi-variate analysis, where past pregnancy (as a standalone) 
was shown to significantly affect MA efficacy. This suggests possible interaction(s) 
between the past pregnancy number and maternal age and/or gestational age. 
Table 10 
Binomial Logistic Regression Output – Protocol Safety 
   95% CI For OR 
Variable OR Significance Lower Higher 
Protocol 1     
Protocol 2 0.386 0.000 0.304 0.489 
Protocol 3 0.524 0.000 0.447 0.613 
Maternal Age 1.093 0.001 1.039 1.150 
Gestational Age 0.825 0.000 0.776 0.877 
The odds-ratios suggest that the 6- to 8- hour protocol (Protocol 2) and the 
simultaneous protocol (Protocol 3) have higher likelihoods of severe adverse events or 
complications compared to the conventional protocol. Both differences are statistically 
significant (p < 0.0001). The safety of the 6- to 8- hour protocol (Protocol 2) is 61% less 
(OR = 0.386, 95% CI: 0.304- 0.489) than the safety of the conventional protocol 
(protocol 1). The safety of the simultaneous protocol (Protocol 3) is 48% less (OR = 
0.524, 95% CI: 0.447 - 0.613) than the safety of the conventional protocol. The null 
hypothesis is therefore rejected. 
The analyses show that maternal age and gestational age affects MA protocol 
safety in a statistically significant manner (p < 0.0001). Each advance in maternal age 
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along the 5-year age blocks used in the analysis reduces the risk of severe complications 
(and/or adverse events) by 9.3%. Each week’s advance in gestational age increases the 
risk of severe complications (and/or adverse events) by 17.5%. 
Summary of Results 
The descriptive results and the results of the bivariate analyses done to validate 
the covariables and the hypothesis testing was provided in this chapter. The assumptions 
of logistic regression were ensured. Both null hypotheses were rejected, with regression 
analyses showing significant differences in efficacy and the safety of the three MA 
protocols when the relevant covariates are controlled for. The efficacy of the 
conventional protocol is comparable to that of the simultaneous protocol while the 6- to 
8- hour protocol has a significantly lower efficacy. Both the simultaneous and the 6- to 8- 
hour protocols showed significantly lower safety that that of the conventional protocol. 
The absolute risk of a severe adverse event or complication was very low for all protocols 
(0.98% for conventional protocol, 2.67% for the 6-to 8-hour, and 1.97% for the 
simultaneous. 
Advancing maternal age as well as advancing gestational age were shown to 
reduce the efficacy of MA, while the effect of past pregnancies on MA efficacy went 
from being significant when considered as a standalone to non significant when 
considered with the other two covariables.  Advancing gestational age was shown to 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this quantitative, retrospective study was to explore the 
relationships of different MA protocols with different dosing intervals to the efficacy and 
safety of the procedures resulting from those protocols. I measured the efficacy of a 
protocol by the percentage of women who had a MA using the said protocol that required 
either an additional abortifacient dose or a vacuum aspiration to complete the procedure. 
Safety of a given MA protocol was measured by the percentage of women who had a MA 
using the said protocol that experienced a complication that required clinical care. 
According to the results, both null hypotheses were rejected. The efficacy of the 
conventional and the simultaneous protocols were comparable while the 6- to 8-hour 
protocol showed a lower efficacy. Both the simultaneous and the 6- to 8-hour protocols 
showed lower safety rates when compared to the conventional protocol. 
A growing proportion of induced abortions across the globe are MAs (Jones & 
Jerman, 2017; Kapp, Eckersberger, Lavelanet, & Rodriguez, 2018). MIFE is registered in 
57 countries (Dunn & Cook, 2014) and MISO in over 100 (Medication Abortion, 2016). 
Regimens of MIFE followed by a dosing interval by MISO is the norm for MAs (Gatter 
et al., 2015; Raymond et al., 2013). This time gap has remained at 24 hours or more over 
the last 2 decades (Creinin et al., 2004; WHO, 2015), making MA a much longer process 
than surgical abortion. If one or both shorter MA protocols are shown to have acceptable 
efficacy and safety (albeit being significantly different from the conventional protocol), 
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they could potentially replace the lengthier conventional protocol, making MA a shorter 
and simpler procedure that many more millions of women find acceptable. 
Interpretation of Findings 
I found the efficacy of the conventional protocol to be comparable to that of the 
simultaneous protocol. The 6-to 8-hour protocol was found to have a significantly lower 
efficacy to that of the others. The safety of both the simultaneous and the 6- to 8-hour 
protocols was significantly lower than that of the conventional protocol. Despite their 
higher risk compared to the conventional protocol (when odds ratios are considered), the 
absolute risk of a severe adverse event or complication that required facility care was 
0.98% for the conventional protocol (i.e., 232 referrals among 24,483 women), 2.67% for 
the 6-to 8-hour protocol (i.e., 103 referrals among 3,869 women), and 1.97% for the 
simultaneous protocol (i.e., 543 referrals among 27,616 women). The rates of severe 
adverse events and complications seen among simultaneous protocol recipients who 
experienced severe adverse events or complications are comparable to the 1.5% serious 
adverse event rate recorded by Creinin et. al. (2007) but higher than the 1.2% reported by 
Schreiber et al. (2005), the 0.2% rate reported by Lohr et. al. (2007), and the 0.1% rate 
reported by Li et al. (2011). Rates of severe adverse events and complications seen 
among the 6- to 8-hour protocol recipients were higher than the 0.6% reported by Creinin 
et. al. (2004). The high rates of clinical referrals observed might be due to substandard 
record keeping at the 24-hour call center of the abortion provision organization. The 
possibility of referrals made due to protocol failures (i.e., where clients are referred for 
additional MISO doses or surgical evacuation) being recorded as being due to 
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complications or severe adverse events cannot be ruled out. Within their study groups, 
some past researchers (i.e., Guest et al. 2007; Tendler et al., 2015) have recorded similar 
adverse event frequencies between the shorter and the conventional protocols. Fox et al., 
(2002), however, recorded higher adverse events among women opting for shorted 
medical protocols. These higher rates were acceptable, and the higher rates of adverse 
events were assumed to be due to the greater overlapping of MIFE and MISO plasma 
peaks. 
In terms of efficacy, the analyses showed that the conventional protocol had a 
1.53% failure rate, while the corresponding rate for the 6- to 8-hour protocol was 7.3% 
and the simultaneous protocol had a failure rate of 1.59%. These results are comparable 
to the efficacy rates shown for the 6- to 8-hour protocol in other studies (Fox et al., 2002; 
Guest et al., 2007; Pymar et al., 2001). However, the efficacy rates seen for the 
simultaneous protocol and the conventional protocols are superior to the 90% to 94% 
efficacy rates seen in past studies (Creinin et al., 2007; Li et al., 2006; Murthy et al., 
2005; Verma et al., 2017). The superior rates could also be explained with the assumption 
that referrals due to protocol failures (where clients are referred for additional 
misoprostol doses or surgical evacuation) being recorded as being due to complications 
or severe adverse events. I addressed this in the limitations of the study and the 
recommendations for future research sections. 
Advancing maternal age and advancing gestational age were shown to reduce MA 
efficacy. The effect of past pregnancies on MA efficacy went from being significant 
when considered as a standalone variable to nonsignificant when considered with 
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gestational age and maternal age as covariables. These findings are of great value because 
to the best of my knowledge, no past study of abortion efficacy had used any covariables 
in their analyses. No past researchers had explored the effect of maternal age or the 
number of past pregnancies on MA efficacy. The effect of gestational age on efficacy 
seen in this study corroborates the results of Fox et al. (2002) who found the efficacy of 
the 6- to 8-hour protocol at 50 to 56 days to be higher than its efficacy at 57 to 63 days of 
gestation. Similar findings were reported by Schreiber et al. (2005) and Verma et al. 
(2017) who found a gestational age over 56 days was a predictor for MA failure. The 
findings did not support Creinin et al.’s (2007) study though, where the authors did not 
find efficacy variations with gestational age up to the 10th week of gestation. Advancing 
gestational age was shown in my study to reduce the safety of MA while advancing 
maternal age showed a small but significant protective effect. No past studies had carried 
out analyses that assessed the effect of these variables on MA safety. 
The study was grounded in postpositivism and empiricism. Empiricism 
recognizes that observation and measurement form the core of scientific study (Trochim, 
2006) and recognizes the role of empirical evidence and the knowledge received through 
observation and experimentation in the formation of ideas (Baird & Kaufmann, 2008). 
The theoretical framework provided by postpositivism (see Tashakkori & Teddlie, 1998; 
Theory of Knowledge, 2015) provided me with valuable guidance in interpreting the 
results and when the results are consulted for the practical implications that they might 
have on MA care provision. Postpositivism ventures beyond the observable (Clark, 1998) 
and posits that objectivity is an ideal that requires critical interpretation (Fischer, 1998). 
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The results of this study show the simultaneous protocol to have comparable efficacy to 
the conventional protocol, while its safety is 58% less compared to the conventional 
protocol. In the data set (without covariates factored in), however, the conventional 
protocol users showed a 1.53% failure rate, while the simultaneous protocol users showed 
a failure rate of 1.59%. With all covariables factored in, the results indicated that if the 
conventional protocol has a 1.53% risk of failure, the risk of failure of the simultaneous 
protocol would be 1.58%. In day-to-day practice, women are very likely to accept this 
small absolute increase in failure in return for a shorter protocol. Postpositivist reasoning 
follows this logic by taking a realist perspective that allows researchers to take the 
realities of life into account when interpreting their results (Theory of Knowledge, 2015).  
The results of this study show promise for recommending the simultaneous 
protocol as an option that can be offered to women seeking a MA prior to the 10th week 
of gestation. The higher failure rate of the 6- to 8-hour protocol combined with its higher 
likelihood of complications and/or severe adverse events does not make it an acceptable 
option. With many women seeking shorter protocols (Iyengar et al., 2016b), the ability to 
offer the simultaneous protocol would be of great importance, while the unsuitability of 
the 6- to 8-hour protocol as having less efficacy and safety would not have a significant 
negative impact. Evidence has demonstrated that women could leave health facility as 
soon as MISO was administered and handle the expulsion on their own (WHO, 2015). 
With the simultaneous protocol, this would mean that a MA prior to the 10th week of 
gestation could become a simple procedure that requires a clinical visit of approximately 




This study had several imitations. The biggest was being a retrospective, 
observational study based on day-to-day clinical data. Observational studies are less 
rigorous than true experiments with randomization (Creswell, 2014). The data spanned 
18 months and came from healthcare worker data entries rather than from robust data-
entry in a research setting. Verifying referral data from the contact center was difficult 
with no source being available for triangulation. The reasons for some referrals might 
have been captured incorrectly by the contact center. Some women who experienced 
adverse events or complications might have sought care outside of the abortion provider 
organization, thereby not being captured in the data. Self-referrals to the National Health 
Service or those seeking care through their general practitioners or walk-in emergency 
centers cannot be ruled out.  
The data related to MA protocols might have inaccuracies, which were impossible 
to rectify. Deviations from the exact administration of MISO (such as route, dosage, or 
timing) might have occurred but were impossible to capture if the documentation shows 
the administration was faultless. The study design did not allow for an experimental 
approach where the independent variable can be manipulated to observe the effects of 
manipulation on the dependent variables (see Frankfort-Nachmias & Nachmias, 2008). A 
women’s choice of MA protocol is respected in abortion care, which ruled out any 
randomization. A true experimental design with random assignment and experimentally 
controlled treatments would be necessary to obtain more accurate estimates for efficacy 
and safety (Creswell, 2014). 
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Finally, the study design only controlled for three covariates that were known to 
impact the safety and the efficacy of MA from a clinical perspective. Gatter et al. (2015) 
showed that in settings where the quality of clinical care is well standardized, poverty and 
educational level does not impact early MA outcomes. However, in real-life 
settingsRamashwar (2013) and Gerdts et. al. (2015) have shown that covariates related to 
the socio-economic status of women, such as education, immigration status, and poverty, 
do impact abortion safety. Such covariates are not captured by the data system of the 
abortion provider, and hence, could not be considered in this study. 
Recommendations for Future Studies 
Future studies should aim to measure the efficacy and the safety of the 
simultaneous protocol with higher accuracy, including how its efficacy and safety 
compare across different gestational ages. Study designs that allow for experimental 
approaches where women who undergo MA are grouped by gestational age and are 
actively followed up with outcomes clearly tracked would allow us to gather more robust 
evidence on the protocols efficacy and safety and how those change with increasing 
gestational age. Such a study would also inform the gestational age up to which this 
protocol could be offered as an out-patient procedure. The complications and adverse 
events of the simultaneous protocol should be better understood. A study where women 
of different gestational ages who receive MAs using this protocol are actively followed 
up for up to 1- to 2- weeks would allow us to plot the different types of adverse events 
and complications as well as their frequencies. 
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Studies that alter the dosage of one or both drugs should be conducted. Groups of 
women who undergo early MA using different dosages could provide us with a study 
where the independent variable (dosages) is manipulated to observe the effects of 
manipulation on the dependent variables (Frankfort-Nachmias & Nachmias, 2008), in this 
case the safety and efficacy. Such a design could even involve randomizing women to the 
different dosage groups, as the potential difference between the different dosages is 
unlikely to lead to unacceptable risks for some groups. Such a true experimental design 
with randomization and experimentally controlled treatments would provide more 
accurate estimates (Creswell, 2014) for efficacy and safety. 
Recommendations for clinical practice 
The results suggest that the simultaneous protocol can be offered in all setting that 
currently offer the conventional protocol for MA up to the 10 weeks of gestation. The 
slightly higher absolute risk of complications and severe adverse events should be 
carefully incorporated into counselling. It should be presented in a manner that makes it 
easy for women to comprehend and compare. The efficacy rates of the conventional and 
the simultaneous protocols must be presented to women in a manner that makes it easy 
for them to understand and compare the slight difference in absolute risk between the 
protocols. All locations that offer the simultaneous protocol must have clear and reliable 
referral options available and all women should be provided with this referral information 
to be used in the case of complications or adverse events. Reliable follow-up mechanisms 
must be in place for women who have post–procedure concerns to seek advice from. 
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Implications for Positive Social Change 
MA is becoming the norm is terminating early pregnancies across the globe, due 
to the process being safer, cheaper, and less medicalized compared to surgical options 
(Simmonds, Beal, & Eagen‐Torkko, 2017; Zane et al., 2015). This is seen in the United 
States (Jones & Kooistra, 2011) as well as Europe. In several European countries, the 
proportion of early abortions carried out through medical methods exceeds 60% (Jones & 
Henshaw, 2002). With MIFE registered in 57 countries (Dunn & Cook, 2014) and MISO 
registered in over 100 countries (Medication Abortion, 2016), the findings of this study 
could pave the way for the simultaneous protocol to be offered to women as a viable 
alternative to the conventional 24- to 36- hour protocol. That will make MA a much 
shorter, simpler procedure. The simultaneous protocol with just one interaction with a 
care provider for its administration could turn MA in to a single day process and 
potentially replace the conventional protocol as the norm. That could make MA more 
enticing and accessible to millions of women worldwide. Even if the simultaneous 
protocol does not replace the conventional protocol, it might become an alternative to be 
offered side-by-side with the conventional protocol. In such a situation, the findings will 
help providers to accurately counsel women on the efficacy and the safety of these MA 
protocols on offer. They could also help women determine which method is the best for 
them, taking both clinical factors as well as factors related to convenience into account. 
The findings could potentially lead to a MA protocol change in the United 
Kingdom. Such a change could have cascading effects on MA protocols used in many 
commonwealth countries. The study findings and a potential UK protocol change could 
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bring the simultaneous protocol to the notice of organizations such as the WHO, United 
Nations Population Fund, International Federation of Gynaecology and Obstetrics, and 
the Royal College of Obstetricians and Gynecologists. These organizations guide care 
practices across the globe. Policy and guideline changes in them can introduce the 
simultaneous protocol across the world, including in settings with restrictive abortion 
legislature. A simpler MA protocol could entice more clinics, hospitals, and practitioners 
to offer it. The simultaneous protocol could become popular among the various online 
platforms that inform women how to conduct early MAs at home, simplifying the process 
for millions of women across the globe. The shift of millions of women to simple, MA 
instead of the riskier, pricier, and harder to access surgical options could reduce serious 
complications. Healthcare systems and governments will be spared resources that are 
currently spent providing expensive surgical abortions as well as managing complications 
of unsafe abortions 
Conclusion 
This retrospective analysis of MA outcomes in women with gestational ages 
below ten weeks showed that the simultaneous protocol has comparable efficacy to the 
conventional MA protocol. The 6- to 8- hour protocol had a significantly lower efficacy. 
Both the simultaneous and the 6- to 8- hour protocols showed higher incidences of severe 
adverse events and complications when compared to the conventional protocol. The 
absolute rates of complications and severe adverse events however were very low. The 
simultaneous protocol is a viable alternative to the conventional protocol and should be 
offered as such to all women seeking MAs prior to the 10 weeks of gestation. Offering it 
104 
 
could give millions more women access to safe and effective single day MAs, cut the 
need for skilled clinicians, and reduce abortion costs for both women and for healthcare 




Aiken, A. R., Digol, I., Trussell, J., & Gomperts, R. (2017). Self-reported outcomes and 
adverse events after medical abortion through online telemedicine: Population 
based study in the Republic of Ireland and Northern Ireland. British Medical 
Journal, 357, j2011. 
Anger, H., Dabash, R., Peña, M., Coutiño, D., Bousiéguez, M., Sanhueza, P., & 
Winikoff, B. (2017). Use of an at-home multilevel pregnancy test and an 
automated telephone system to simplify medical abortion follow-up. 
Contraception, 95(5), 518. 
Arvidsson, C., Hellborg, M., & Gemzell-Danielsson, K. (2005). Preference and 
acceptability of oral versus vaginal administration of misoprostol in medical 
abortion with mifepristone. European Journal of Obstetrics & Gynecology and 
Reproductive Biology, 123(1), 87-91. 
Ashok, P. W., Templeton, A., Wagaarachchi, P. T., & Flett, G. M. (2002). Factors 
affecting the outcome of early medical abortion: A review of 4132 consecutive 
cases. BJOG: An International Journal of Obstetrics & Gynaecology, 109(11), 
1281-1289. 
Avrech, O. M., Golan, A., Weinraub, Z., Bukovsky, I., & Caspi, E. (1991). Mifepristone 
(RU486) alone or in combination with a prostaglandin analogue for termination of 
early pregnancy: A review. Fertility and Sterility, 56(3), 385-393. 
Baird, F. E., & Kaufmann, W. A. (2008). Philosophical classics: From Plato to Derrida. 
Taylor & Francis, New York, NY: Publisher. 
106 
 
Baldwin, M. K., Bednarek, P. H., & Russo, J. (2017). Outcomes of very early medical 
and surgical abortion. Contraception, 96(4), 270-271. 
Baulieu, E. E. (1985). RU486: An antiprogestin steroid with contragestive activity in 
women. The Antiprogestin Steroid RU, 486, 1-25. 
Berer, M. (2004). National laws and unsafe abortion: The parameters of change. 
Reproductive Health Matters, 12(24), 1-8. 
Berer, M. (2005). Medical abortion: Issues of choice and acceptability. Reproductive 
Health Matters, 13(26), 25-34. 
Berer, M. (2017). Abortion law and policy around the world: In search of 
decriminalization. Health and Human Rights, 19(1), 13. 
Bhattacharjee, N., Saha, S. P., Ghoshroy, S. C., Bhowmik, S., & Barui, G. (2008). A 
randomised comparative study on sublingual versus vaginal administration of 
misoprostol for termination of pregnancy between 13 to 20 weeks. Australian and 
New Zealand Journal of Obstetrics and Gynaecology, 48(2), 165-171. 
Biggs, M. A., Upadhyay, U. D., McCulloch, C. E., & Foster, D. G. (2017). Women’s 
mental health and well-being 5 years after receiving or being denied an abortion: 
A prospective, longitudinal cohort study. JAMA Psychiatry, 74(2), 169-178. 
Bracken, H., Dabash, R., Tsertsvadze, G., Posohova, S., Shah, M., Hajri, S.,... Platais, I. 
(2014). A two-pill sublingual misoprostol outpatient regimen following 
mifepristone for medical abortion through 70 days’ LMP: A prospective 
comparative open-label trial. Contraception, 89(3), 181-186. 
Brewer, M. B., & Crano, W. D. (2000). Research design and issues of validity. Handbook 
107 
 
of Research Methods in Social and Personality Psychology, 3-16. 
Cameron, S., Glasier, A., Dewart, H., & Johnstone, A. (2010). Women’s experiences of 
the final stage of early medical abortion at home: Results of a pilot survey. 
Journal of Family Planning and Reproductive Health Care, 36(4), 213-216. 
Care Quality Commission. (2012). The state of health care and adult social care in 
England in 2011/12 (Vol. 763). London, UK: The Stationery Office. 
Care Quality Commission. (2016). Termination of pregnancy service inspections roll-out. 
Retrieved from http://www.cqc.org.uk/news/stories/termination-pregnancy-
service-inspections-roll-out 
Cavet, S., Fiala, C., Scemama, A., & Partouche, H. (2017). Assessment of pain during 
medical abortion with home use of misoprostol. The European Journal of 
Contraception & Reproductive Health Care, 22(3), 207-211. 
Chamberlain, J. M. (2017). Malpractice, criminality, and medical regulation: Reforming 
the role of the GMC in fitness to practise panels. Medical Law Review, 25(1), 1-
22. 
Chen, M. J., & Creinin, M. D. (2015). Mifepristone with buccal misoprostol for medical 
abortion: A systematic review. Obstetrics & Gynecology, 126(1), 12-21. 
Clark, A. M. (1998). The qualitative‐quantitative debate: Moving from positivism and 
confrontation to postpositivism and reconciliation. Journal of Advanced Nursing, 
27(6), 1242-1249. 
Clark, W. H., Gold, M., Grossman, D., & Winikoff, B. (2007). Can mifepristone medical 
abortion be simplified? A review of the evidence and questions for future 
108 
 
research. Contraception, 75 (4), 245-250. 
Cleland, K., Creinin, M. D., Nucatola, D., Nshom, M., & Trussell, J. (2013). Significant 
adverse events and outcomes after medical abortion. Obstetrics and Gynecology, 
121(1), 166. 
Coe, R. (2002). It’s the effect size, stupid: What effect size is and why it is important. 
Retrieved from http://www.leeds.ac.uk/educol/documents/00002182.htm 
Core Outcome Measures in Effectiveness Trials (COMET) Initiative. (2017). Developing 
a core outcome set for induced abortion. Retrieved from http://www.comet-
initiative.org/studies/details/779?result=true 
Constant, D., Harries, J., Daskilewicz, K., Myer, L., & Gemzell-Danielsson, K. (2017). Is 
self-assessment of medical abortion using a low-sensitivity pregnancy test 
combined with a checklist and phone text messages feasible in South African 
primary healthcare settings? A randomized trial. PloS One, 12(6), e0179600. 
Coombes, R. (2008). Obstetricians seek recognition for Chinese pioneers of safe 
abortion. BMJ: British Medical Journal, 336(7657), 1332. 
Creinin, M. D., & Chen, M. J. (2016). Medical abortion reporting of efficacy: the MARE 
guidelines. Contraception, 94(2), 97-103. 
Creinin, M. D., Fox, M. C., Teal, S., Chen, A., Schaff, E. A., Meyn, L. A., & MOD Study 
Trial Group. (2004). A randomized comparison of MISO 6 to 8 hours versus 24 
hours after MIFE for abortion. Obstetrics & Gynecology, 103(5, Part 1), 851-859. 
Creinin, M. D., & Chen, M. J. (2016). Medical abortion reporting of efficacy: the MARE 
guidelines. Contraception, 94(2), 97-103. 
109 
 
Creinin, M. D., Schreiber, C. A., Bednarek, P., Lintu, H., Wagner, M. S., & Meyn, L. A. 
(2007). Mifepristone and misoprostol administered simultaneously versus 24 
hours apart for abortion: a randomized controlled trial. Obstetrics & Gynecology, 
109(4), 885-894. 
Creswell, J. W. (2013). Research design: Qualitative, quantitative, and mixed methods 
approaches. Thousand Oakes, London. Sage publications. 
Dabash, R., Chong, E., Bracken, H., Tsereteli, T., Abrahamyan, R., Hajri, S., ... 
Sadikova, D. (2017). A randomized controlled trial comparing repeat doses of 400 
mcg sublingual to buccal misoprostol after mifepristone for termination of 
pregnancy 13–21 weeks. Contraception, 95(5), 515. 
Danielsson, K. G., Marions, L., Rodriguez, A., Spur, B. W., Wong, P. Y. K., & 
Bygdeman, M. (1999). Comparison between oral and vaginal administration of 
misoprostol on uterine contractility. Obstetrics & Gynecology, 93(2), 275-280. 
Davies, H. T., & Nutley, S. M. (1999). The rise and rise of evidence in health care. Public 
Money and Management, 19(1), 9-16. 
DePoy, E., & Gitlin, L. N. (2015). Introduction to research-e-book: Understanding and 
applying multiple strategies. Elsevier Health Sciences. St. Louise, Missouri.  
http://evolve.elsevier.com 
Dellapenna, J. W. (2006). Dispelling the myths of abortion history. Durham, NC: 
Carolina Academic Press 
Devereux, G. (1954). A typological study of abortion in 350 primitive, ancient and pre-
industrial societies. In H. Rosen (Ed.), Therapeutic Abortion (p. 98). New York, 
110 
 
NY: Julian Press Inc. 
Devereux, G. (1967). A typological study of abortion in 350 primitive, ancient, and pre-
industrial societies. In H. Rosen (Ed.), Abortion in America: Medical, psychiatric, 
legal, anthropological, and religious considerations (pp. 97-152). Boston, MA: 
Beacon Press.  
Dunn, S., & Cook, R. (2014). Medical abortion in Canada: Behind the times. Canadian 
Medical Association Journal, 186(1), 13-14. 
Fant, M. B., & Lefkowitz, M. R. (2016). Women's life in Greece and Rome: A source 
book in translation. City, State: Bloomsbury Publishing. 
Faúndes, A. (2011). The combination of mifepristone and misoprostol for the termination 
of pregnancy. International Journal of Gynecology & Obstetrics, 115(1), 1-4. 
Fiala, C., Cameron, S., Bombas, T., Parachini, M., Saya, L., & Gemzell-Danielsson, K. 
(2014). Pain during medical abortion, the impact of the regimen: A neglected 
issue? A review. The European Journal of Contraception & Reproductive Health 
Care, 19(6), 404-419. 
Filippi, V., Chou, D., Ronsmans, C., Graham, W., & Say, L. (2016). Disease Control 
Priorities, Third Edition (Volume 2): Reproductive, Maternal, Newborn, and 
Child Health. https://doi.org/10.1596/978-1-4648-0348-2 
Fischer, F. (1998). Beyond empiricism: Policy inquiry in postpositivist perspective. 
Policy Studies Journal, 26(1), 129-146. 
Foster, D. G., Steinberg, J. R., Roberts, S. C., Neuhaus, J., & Biggs, M. A. (2015). A 
comparison of depression and anxiety symptom trajectories between women who 
111 
 
had an abortion and women denied one. Psychological Medicine, 45(10), 2073-
2082. 
Francome, C. (2017). Abortion in the USA and the UK. London, UK. Routledge. 
https://doi.org/10.4324/9781315263489 
Frankfort-Nachmias, C., & Nachmias, D. (2008). Research methods in the social sciences 
(7th ed.). New York, NY: Worth. 
Fox, M. C., Creinin, M. D., & Harwood, B. (2002). Mifepristone and vaginal misoprostol 
on the same day for abortion from 50 to 63 days’ gestation. Contraception, 66(4), 
225-229. 
Ganatra, B., Tuncalp, O., Johnston, H. B., Johnson Jr, B. R., Gulmezoglu, A. M., & 
Temmerman, M. (2014). From concept to measurement: Operationalizing WHO’s 
definition of unsafe abortion. Bulletin of the World Health Organization, 92(3), 
155-155. 
Gatter, M., Cleland, K., & Nucatola, D. L. (2015). Efficacy and safety of medical 
abortion using MIFE and buccal MISO through 63 days. Contraception, 91(4), 
269-273. 
Gaudineau, A., Agostini, A., & Vayssière, C. (2016). Induced abortion: Guidelines for 
clinical practice-Methods. Journal de Gynecologie, Obstetrique et Biologie de la 
Reproduction, 45(10), 1459-1461. 
Gerdts, C., DePiñeres, T., Hajri, S., Harries, J., Hossain, A., Puri, M.,... Foster, D. G.  
(2015). Denial of abortion in legal settings. Journal of Family Planning and 
Reproductive Health Care, 41(3), 161-163. 
112 
 
Gopal, A. K., Ganamurali, S., & Kumari, B. (2017). Effectiveness of evidence-based 
regimen for medical abortion over conventional methods. International Journal of 
Reproduction, Contraception, Obstetrics and Gynecology, 6(3), 881-886. 
Gordon, L., & Mass, B. (1976). Woman's body, woman's right: A social history of birth 
control in America. New York. NY: Grossman Publishers.  
Grossman, D., & Goldstone, P. (2015). Mifepristone by prescription: A dream in the 
United States but reality in Australia. Contraception, 92(3), 186-189. 
Guest, J., Chien, P. F. W., Thomson, M. A. R., & Kosseim, M. L. (2007). Randomised 
controlled trial comparing the efficacy of same‐day administration of mifepristone 
and misoprostol for termination of pregnancy with the standard 36 to 48 hour 
protocol. BJOG: An International Journal of Obstetrics & Gynaecology, 114(2), 
207-215. 
Haimov-Kochman, R., Arbel, R., Sciaky-Tamir, Y., Brzezinski, A., Laufer, N., & Yagel, 
S. (2007). Risk factors for unsuccessful medical abortion with mifepristone and 
misoprostol. Acta Obstetrica Gynecologica Scandinavia, 86, 462–6 
Hamoda, H., & Templeton, A. (2010). Medical and surgical options for induced abortion 
in first trimester. Best practice & research. Clinical Obstetrics & Gynaecology, 
24(4), 503-516. 
Hjørland, B. (2005). Empiricism, rationalism and positivism in library and information 
science. Journal of Documentation, 61(1), 130-155. 




Honkanen, H., Piaggio, G., Hertzen, H., Bártfai, G., Erdenetungalag, R., Gemzell‐
Danielsson, K.,... Thi Nhu Ngoc, N. (2004). WHO multinational study of three 
misoprostol regimens after mifepristone for early medical abortion. BJOG: An 
International Journal of Obstetrics & Gynaecology, 111(7), 715-725. 
Iyengar, K., Klingberg‐Allvin, M., Iyengar, S. D., Paul, M., Essén, B., & Gemzell‐
Danielsson, K. (2016). Home use of misoprostol for early medical abortion in a 
low resource setting: Secondary analysis of a randomized controlled trial. Acta 
Obstetricia et Gynecologica Scandinavica, 95(2), 173-181. 
Jones, R. K., & Henshaw, S. K. (2002). Mifepristone for early medical abortion: 
Experiences in France, Great Britain and Sweden. Perspectives on Sexual and 
Reproductive Health, 34(3), 154-161. 
Jones, R. K., & Jerman, J. (2017). Abortion incidence and service availability in the 
United States, 2014. Perspectives on Sexual and Reproductive Health, 49(1), 17-
27. 
Jones, R. K., & Kooistra, K. (2011). Abortion incidence and access to services in the 
United States, 2008. Perspectives on Sexual and Reproductive Health, 43(1), 41-
50. 
Kapp, N., Borgatta, L., Ellis, S. C., & Stubblefield, P. (2006). Simultaneous very low 
dose mifepristone and vaginal misoprostol for medical abortion. Contraception, 
73(5), 525-527. 
Kapp, N., Eckersberger, E., Lavelanet, A., & Rodriguez, M. I. (2018). Medical abortion 
in the late first trimester: A systematic review. Contraception, 99(2), 77-86. 
114 
 
Kassebaum N. J., Bertozzi-Villa A, Coggeshall M. S., Shackelford K. A., Steiner C, 
Heuton K. R. (2014). Global, regional, and national levels and causes of maternal 
mortality during 1990–2013: A systematic analysis for the Global Burden of 
Disease Study. The Lancet, 384(9947), 980-1004.  doi:10.1016/S0140-
6736(14)60696-6 PubMed  
Khan, R. U., El-Refaey, H., Sharma, S., Sooranna, D., & Stafford, M. (2004). Oral, 
rectal, and vaginal pharmacokinetics of misoprostol. Obstetrics & Gynecology, 
103(5), 866-870. 
Kulier, R., Gulmezoglu, A. M., Hofmeyr, G. J., Cheng, L. N., & Campana, A. (2004). 
Medical methods for first trimester abortion. Cochrane Database Systematic 
Reviews, 2(2). 
Lefebvre, P., Cotte, M., Monniez, N., & Norel, G. (2008). The role of parity in medical 
abortion up to 49 days of amenorrhoea. The European Journal of Contraception 
& Reproductive Health Care, 13(4), 404-411. 
Levin, K. A. (2006). Study design III: Cross-sectional studies. Evidence-Based Dentistry, 
7(1), 24-25. 
Levine, K., & Cameron, S. T. (2009). Women’s preferences for method of abortion and 
management of miscarriage. Journal of Family Planning and Reproductive 
Health Care, 35(4), 233-235. 
Li, Y.-T., Lee, W.-L., & Wang, P.-H. (2017). Medical abortion. Journal of the Chinese 




Lie, M. L., Robson, S. C., & May, C. R. (2008). Experiences of abortion: A narrative 
review of qualitative studies. BMC Health Services Research, 8(1), 150. 
Lo, S. S. T., & Ho, P. C. (2015). First-trimester medical abortion service in Hong Kong. 
Hong Kong Medical Journal, 21 (5), 462–467. 
Lohr, P. A., Reeves, M. F., Hayes, J. L., Harwood, B., & Creinin, M. D. (2007). Oral 
mifepristone and buccal misoprostol administered simultaneously for abortion: a 
pilot study. Contraception, 76(3), 215-220. 
Louie, K. S., Tsereteli, T., Chong, E., Aliyeva, F., Rzayeva, G., & Winikoff, B. (2014). 
Acceptability and feasibility of mifepristone medical abortion in the early first 
trimester in Azerbaijan. The European Journal of Contraception & Reproductive 
Health Care, 19(6), 457-464. 
Louie, K. S., Chong, E., Tsereteli, T., Avagyan, G., Vardanyan, S., & Winikoff, B. 
(2014). The introduction of first trimester medical abortion in Armenia. 
Reproductive Health Matters, 22(sup44), 56-66. 
Løkeland, M., Iversen, O. E., Engeland, A., Økland, I., & Bjørge, L. (2014). Medical 
abortion with mifepristone and home administration of misoprostol up to 63 days 
gestation. Acta Obstetricia Et Gynecologica Scandinavica, 93(7), 647-653. 
Mählck, C.-G., & Bäckström, T. (2017). Follow-up after early medical abortion: 
Comparing clinical assessment with self-assessment in a rural hospital in northern 
Norway. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 
213, 1–3. https://doi.org/10.1016/j.ejogrb.2017.03.034 
Manjikian, M. (2013). Positivism, postpositivism, and intelligence analysis. International 
116 
 
Journal of Intelligence and Counter Intelligence, 26(3), 563-582. 
McEachan, R. R., Lawton, R. J., Jackson, C., Conner, M., & Lunt, J. (2008). Evidence, 
theory and context: Using intervention mapping to develop a worksite physical 
activity intervention. BMC Public Health, 8(1), 326. 
McKinley, C., Thong, K. J., & Baird, D. T. (1993). Pregnancy: The effect of dose of 
mifepristone and gestation on the efficacy of medical abortion with mifepristone 
and misoprostol. Human Reproduction, 8(9), 1502-1505. 
Medication Abortion. (2016). Misoprostol registration worldwide. Retrieved from 
http://www.medicationabortions.com/misoprostol 
Meena, S. R. (2016). Comparative study of mifepristone with vaginal misoprostol for 
first trimester termination of pregnancy at different gestational ages. The Journal 
of Obstetrics and Gynecology of India, 66(6), 426-430. 
Metcalfe, M., & Lynch, M. (2002). A critique of generalizability in interpretive research. 
Australasian Journal of Information Systems, 10(1). 
Morris, J. L., Winikoff, B., Dabash, R., Weeks, A., Faundes, A., Gemzell‐Danielsson, K., 
... Visser, G. H. (2017). FIGOs updated recommendations for misoprostol used 
alone in gynecology and obstetrics. International Journal of Gynecology & 
Obstetrics, 138(3), 363-366. 
Murthy, A. S., Creinin, M. D., Harwood, B., & Schreiber, C. (2005). A pilot study of 
mifepristone and misoprostol administered at the same time for abortion up to 49 
days gestation. Contraception, 71(5), 333-336. 
Newhall, E. P., & Winikoff, B. (2000). Abortion with mifepristone and misoprostol: 
117 
 
Regimens, efficacy, acceptability and future directions. American Journal of 
Obstetrics and Gynecology, 183(2), S44-S53. 
Newmann, S. J., Dalve‐Endres, A., Diedrich, J. T., Steinauer, J. E., Meckstroth, K., & 
Drey, E. A. (2010). Cervical preparation for second trimester dilation and 
evacuation. The Cochrane Library. Retrieved from 
http://www.academia.edu/download/46034405/Cervical_preparation_for_second_
trimeste20160528-23335-end26k.pdf 
National Health Service. (2017). Health research authority: Confidentiality advisory 
group. Retrieved from https://www.hra.nhs.uk/approvals-amendments/what-
approvals-do-i-need/confidentiality-advisory-group/ 
Nijman, T. A., Voogdt, K. G., Teunissen, P. W., van der Voorn, P. J. J., de Groot, C. J., 
& Bakker, P. C. (2017). Association between infection and fever in terminations 
of pregnancy using misoprostol: A retrospective cohort study. BMC Pregnancy 
and Childbirth, 17(1), 7. 
Niinimäki, M., Pouta, A., Bloigu, A., Gissler, M., Hemminki, E., Suhonen, S., & 
Heikinheimo, O. (2009). Immediate complications after medical compared with 
surgical termination of pregnancy. Obstetrics & Gynecology, 114(4), 795-804. 
Ngo, T D., Park, M. H., Shakur, H., & Free, C. (2011). Comparative effectiveness, safety 
and acceptability of medical abortion at home and in a clinic: A systematic 
review. Bulletin of the World Health Organization, 89(5), 360-370. 
Olsen, W. (2004). Triangulation in social research: Qualitative and quantitative methods 
can really be mixed. Developments in Sociology, 20, 103-118. 
118 
 
Orrantia, E., & Armand, S. S. (2017). The occasional medical termination of pregnancy. 
Canadian Journal of Rural Medicine, 22(1), 21-26. 
Ota, E., Ganchimeg, T., Mori, R., & Souza, J. P. (2014). Risk factors of pre-
eclampsia/eclampsia and its adverse outcomes in low-and middle-income 
countries: a WHO secondary analysis. PloS One, 9(3), e91198. 
Pawde, A. A., Ambadkar, A., & Chauhan, A. R. (2016). A study of incomplete abortion 
following medical method of abortion. Journal of Obstetrics and Gynaecology of 
India, 66(4), 239–243. https://doi.org/10.1007/s13224-015-0673-1 
Potts, M. (2010). Abortion perspectives. The European Journal of Contraception and 
Reproductive Health Care, 15, 157-159. 
Powell-Jackson, T., Acharya, R., Filippi, V., & Ronsmans, C. (2015). Delivering medical 
abortion at scale: a study of the retail market for medical abortion in Madhya 
Pradesh, India. PloS One, 10(3), e0120637. 
Purcell, C., Cameron, S., Lawton, J., Glasier, A., & Harden, J. (2017). Self‐management 
of first trimester medical termination of pregnancy: A qualitative study of 
womens experiences. BJOG: An International Journal of Obstetrics & 
Gynaecology. 124(13), 2001-2008. 
Pymar, H. C., Creinin, M. D., & Schwartz, J. L. (2001). Mifepristone followed on the 
same day by vaginal misoprostol for early abortion. Contraception, 64(2), 87-92. 
Ramashwar, S. (2013). Youth, poverty linked to unsafe abortion among women in 
Ghana. International Perspectives on Sexual and Reproductive Health, 39(1), 48. 
Raymond, E. G., & Grimes, D. A. (2012). The comparative safety of legal induced 
119 
 
abortion and childbirth in the United States. Obstetrics & Gynecology, 119(2, Part 
1), 215-219. 
Raymond, E. G., Shannon, C., Weaver, M. A., & Winikoff, B. (2013). First-trimester 
medical abortion with mifepristone 200 mg and misoprostol: A systematic review. 
Contraception, 87(1), 26-37. 
RCOG. (2011). Royal College of Obstetricians and Gynecologists. The care of women 
requesting induced abortion: evidence-based clinical guideline number 7. RCOG 
Press, London. Retrieved from 
http://www.contraceptionjournal.org/article/S0010-7824(12)00643-
9/fulltext#back-bb0035  
Regan, L., & Glasier, A. (2017). The British 1967 Abortion Act—still fit for purpose?. 
The Lancet, 390(10106), 1936-1937. 
Reynolds, P. D. (1971). A primer in theory construction. Taylor & Francis. London, UK. 
Routledge.  
Rubin, P. (2014). Revalidation: A world first in medical regulation. Arab Journal of 
Urology, 12(1), 83-85. 
Sang, G. W. (1999). A large scale introductory trial on termination of early pregnancy by 
mifepristone in combination with different prostaglandins. Zhong Guo Lin 
Chuang Yao Li Xue Za Zhi, 15, 323-329. 
Sanhueza Smith, P., Peña, M., Dzuba, I. G., Martinez, M. L. G., Peraza, A. G. A., 
Bousiéguez, M., ... & Winikoff, B. (2014). Safety, efficacy and acceptability of 
outpatient mifepristone-misoprostol medical abortion through 70 days since last 
120 
 
menstrual period in public sector facilities in Mexico City. Reproductive Health 
Matters, 22(44), 75-82. 
Schaff, E. A., Fielding, S. L., & Westhoff, C. (2001). Randomized trial of oral versus 
vaginal misoprostol at one day after mifepristone for early medical abortion. 
Contraception, 64(2), 81-85. 
Schmuckler, M. A. (2001). What is ecological validity? A dimensional analysis. Infancy, 
2(4), 419-436. 
Schreiber, C. A., Creinin, M. D., Harwood, B., & Murthy, A. S. (2005). A pilot study of 
mifepristone and misoprostol administered at the same time for abortion in 
women with gestation from 50 to 63 days. Contraception, 71(6), 447-450. 
Sedgh, G., Singh, S., & Hussain, R. (2014). Intended and unintended pregnancies 
worldwide in 2012 and recent trends. Studies in Family Planning, 45(3), 301-314. 
Sedgwick, P. (2014a). Retrospective cohort studies: Advantages and disadvantages. BMJ: 
British Medical Journal (Online), 348. 
Sedgwick, P. (2014b). Cross sectional studies: Advantages and disadvantages. BMJ: 
British Medical Journal, 348. 
Shannon, C., Wiebe, E., Jacot, F., Guilbert, E., Dunn, S., Sheldon, W. R., & Winikoff, B. 
(2006). Regimens of misoprostol with mifepristone for early medical abortion: A 
randomised trial. BJOG: An International Journal of Obstetrics & Gynaecology, 
113(6), 621-628. 
Sharp, A., Navaratnam, K., Abreu, P., & Alfirevic, Z. (2016). Short versus standard 
mifepristone and misoprostol regimen for second-and third-trimester termination 
121 
 
of pregnancy for fetal anomaly. Fetal Diagnosis and Therapy, 39(2), 140-146. 
Shaw, K. A., Topp, N. J., Shaw, J. G., & Blumenthal, P. D. (2013). Mifepristone-
misoprostol dosing interval and effect on induction abortion times: A systematic 
review. Obstetrics and Gynecology, 121(6), 1335. 
Sheldon, W. R., Durocher, J., Dzuba, I., Sayette, H., Redwine, D., Cardenas, M., & 
Winikoff, B. (2017). Buccal vs. sublingual misoprostol alone for early pregnancy 
termination in two Latin American settings: A randomized trial. Contraception, 
95(5), 516. 
Simmonds, K. E., Beal, M. W., & Eagen‐Torkko, M. K. (2017). Updates to the US Food 
and Drug Administration regulations for mifepristone: Implications for clinical 
practice and access to abortion. Journal of Midwifery & Women’s Health, 62(3), 
348-352. 
Singh, S., Hossain, A., Maddow-Zimet, I., Vlassoff, M., Bhuiyan, H. U., & Ingerick, M. 
(2017). The incidence of menstrual regulation procedures and abortion in 
Bangladesh, 2014. International Perspectives on Sexual and Reproductive Health, 
43(1), 1-11. 
Sjöström, S., Dragoman, M., Fønhus, S. M., Ganatra, B., & Gemzell‐Danielsson, K. 
(2017). Effectiveness, safety and acceptability of non‐physician provision of first 
trimester medical termination of pregnancy: a systematic review. BJOG: An 
International Journal of Obstetrics & Gynaecology. 2017(124), 1928–1940. 
Soon, J. A., Costescu, D., & Guilbert, E. (2016). Medications used in evidence-based 
regimens for medical abortion: An overview. Journal of Obstetrics and 
122 
 
Gynaecology Canada, 38(7), 636–645. https://doi.org/10.1016/j.jogc.2016.04.005 
Swahn, M. L., & Bygdeman, M. (1989). Termination of early pregnancy with RU 486 
(mifepristone) in combination with a prostaglandin analogue (sulprostone). Acta 
Obstetricia Et Gynecologica Scandinavica, 68(4), 293-300. 
Swica, Y., Chong, E., Middleton, T., Prine, L., Gold, M., Schreiber, C. A., & Winikoff, 
B. (2013). Acceptability of home use of mifepristone for medical abortion. 
Contraception, 88(1), 122-127. 
Tang, O. S., Gemzell-Danielsson, K., & Ho, P. C. (2007). Misoprostol: Pharmacokinetic 
profiles, effects on the uterus and side-effects. International Journal of 
Gynecology & Obstetrics, 99, S160-S167. 
Tashakkori, A., & Teddlie, C. (1998). Mixed methodology: Combining qualitative and 
quantitative approaches (Vol. 46). Sage. Thousand Oakes, London. 
Taylor, G. L. (1998). Womens experience of abortion: A qualitative study. Retrieved 
from http://nrfnexus.nrf.ac.za/handle/20.500.11892/21936 
Tendler, R., Bornstein, J., Kais, M., Masri, I., & Odeh, M. (2015). Early versus late 
misoprostol administration after mifepristone for medical abortion. Archives of 
Gynaecology And Obstetrics, 292(5), 1051–1054.  
Theory of Knowledge. (2015). Empiricism. Retrieved  from 
http://www.theoryofknowledge.info/sources-of-knowledge/empiricism/ 
Thiebaut, M., Firquet, A., Pintiaux, A., Vande, K. C., … Nisolle, M. (2017). 
Retrospective assessment of the influence of gestational age on the first trimester 
medical abortion efficiency. Revue Medicale de Liege, 72(4), 193. 
123 
 
Trochim, W.M.K. (2006). Positivism & Postpositivism. In research methods knowledge 
base. Retrieved from http://www.socialresearchmethods.net/kb/positvsm.php 
Trochim, W. M., & Donnelly, J. P. (2001). Research methods knowledge base. Retrieved 
from http://www.anatomyfacts.com/research/researchmethodsknowledgebase.pdf 
Tsereteli, T., Chong, E., Louie, K., & Bokhua, Z. (2016). Acceptability and feasibility of 
400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in 
Georgia. The European Journal of Contraception & Reproductive Health Care: 
The Official Journal of the European Society of Contraception, 21(5), 367-371. 
Upadhyay, U. D., Desai, S., Zlidar, V., Weitz, T. A., Grossman, D., Anderson, P., & 
Taylor, D. (2015). Incidence of emergency department visits and complications 
after abortion. Obstetrics & Gynecology, 125(1), 175-183. 
Urquhart, D. R., Templeton, A. A., Shinewi, F., Chapman, M., Hawkins, K., McGarry, J., 
... & Lunan, C. B. (1997). The efficacy and tolerance of mifepristone and 
prostaglandin in termination of pregnancy of less than 63 days gestation; UK 
multicentre study—Final results. Contraception, 55(1), 1-5. 
Verma, M. L., Singh, U., Singh, N., Sankhwar, P. L., & Qureshi, S. (2017). Efficacy of 
concurrent administration of mifepristone and misoprostol for termination of 
pregnancy. Human Fertility, 20(1), 43-47. 
Vrachnis, N., Zygouris, D., Lolos, M., Dimitrakaki, A., & Salakos, N. (2016). First 
trimester medical abortion: The several merits of combination mifepristone-
misoprostol. Hungarian Journal of Obstetrics and Gynecology, 15(1). 
Whitehouse, K. C., Kim, C. R., Ganatra, B., Duffy, J. M., Blum, J., Brahmi, D., ... & 
124 
 
Winikoff, B. (2017). Standardizing abortion research outcomes (STAR): A 
protocol for developing, disseminating and implementing a core outcome set for 
medical and surgical abortion. Contraception, 95(5), 437-441. 
Winikoff, B., Sivin, I., Coyaji, K. J., Cabezas, E., Bilian, X., Sujuan, G., ... & Ellertson, 
C. (1997). Safety, efficacy, and acceptability of medical abortion in China, Cuba, 
and India: A comparative trial of mifepristone-misoprostol versus surgical 
abortion. American Journal of Obstetrics And Gynecology, 176(2), 431-437. 
World Health Organization. (1992). International Classification of Diseases and Related 
Health Problems, World Health Organization, Geneva. Retrieved from 
http://apps.who.int/classifications/icd10/browse/2010/en 
World Health Organization. (2010). WHO model list of essential medicines: 16th list 
(updated) March 2010. Retrieved from 
http://apps.who.int/iris/bitstream/10665/70643/1/a95060_eng.pdf 
World Health Organization. (2011). Unsafe abortion: Global and regional estimates of 
the incidence of unsafe abortion and associated mortality in 2008, Geneva, WHO, 
2011. Retrieved from http://www.popline.org/node/661373 
World Health Organization. (2012). Safe abortion: Technical and policy guidance for 
health systems, Geneva, WHO, 2012. Retrieved from: 
http://appswhoint/iris/bitstream/10665/70914/1/9789241548434_engpdf. 
World Health Organization. (2015a). Safe abortion: Technical & policy guidance for 





World Health Organization. (2015b). Health Worker Role in Providing Safe Abortion 
Care and Post–Abortion Contraception. World Health Organization. 
Wu, Y., & Wu, X. (1958). A report of 300 cases using vacuum aspiration for termination 
of pregnancy. Chinese Journal of Obstetrics and Gynaecology, 447, 9. 
Yan, C. (1983). Clinical observation on termination of first and second trimester 
pregnancies by prostaglandin E_1 analogue vaginal pessaries (ONO-802)[J]. 
Beijing Medical Journal, 2, 010. 
Yu, C. H., & Ohlund, B. (2010). Threats to validity of research design. Retrieved 
January, 12, 2012. http://www.creative-wisdom.com/teaching/WBI/threat.shtml 
Zane, S., Creanga, A. A., Berg, C. J., Pazol, K., Suchdev, D. B., Jamieson, D. J., & 
Callaghan, W. M. (2015). Abortion-related mortality in the United States: 1998-
2010. Obstetrics and Gynecology, 126(2), 258-265. 
Zieman, M., Fong, S. K., Benowitz, N. L., Banskter, D., & Darney, P. D. (1997). 
Absorption kinetics of misoprostol with oral or vaginal administration. Obstetrics 
& Gynecology, 90(1), 88-92. 
Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., ...  
Moher, D. (2008). Improving the reporting of pragmatic trials: An extension of 
the CONSORT statement. BMJ, 337, a2390. 
 
